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1. INTRODUCTION 1 
1. Introduction 
 
Aims 
 
Microglia Therapy: Diseases like Alzheimer or Multiple Sclerosis have been linked 
to a continuous deterioration of the resident microglia cell population [1]. The brain, 
like other organs, also suffers from age related inflammation (“inflamm-aging”) [2] and 
chronic activation of microglia. 
A cell therapy could aim to replace deteriorated microglia or to regulate the excessive 
activation of microglia in age. 
We wanted to differentiate microglia from adult stem cells (Paper 1 and 2) and to 
proof their function (phagocytosis, oxidative burst, migration). Then, we planned to 
transplant their progenitors and the differentiated microglia (Paper 3 and additional 
data). We also wanted to transplant mesenchymal stem cells (MSC) since MSC are 
known to regulate inflammation [3]. 
 
We aimed to: 
 
1. Differentiate microglia from mouse bone marrow and proof their function 
(Paper 1 and 2) 
2. Observe migration, survival, morphology in co-culture with brain tissue (Paper 
1 and 2) 
3. Transplant microglia progenitors, microglia and MSC, track cells and 
stereological measurement of microglia numbers and activity (Paper 3 and 
additional data) 
 
Differentiation of Microglia: For transplantation of microglia progenitors and mature 
microglia, it is necessary to prove the capacity to differentiate to functional microglia 
(Paper 1 and 2). For application in a cell therapy we have not only to prove 
phenotype (Morphology, markers) but also the function of these cells (Phagocytosis, 
oxidative burst). 
Several protocols exist in literature to differentiate microglia [4-7].  
They have been differentiated from peripheral blood monocytes [4], bone marrow [5, 
6] and from embryonic stem cells (ESC) [7] (Table 1). All of these protocols make use 
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of the non-adherent fraction of bone marrow cells. Primary microglia can be isolated 
from the brain and the central nervous system (CNS). 
Sucessful differentiation has been tested in literature by display of the typical 
microglia morphology (Ramification) and the expression of non-exclusive markers [6]. 
Furthermore, as a proof of principle, we planned to test the capacity of the 
differentiated cells to perform functions of primary microglia (Phagocytosis, oxidative 
burst) before use in transplantation.  
 
 
Table 1: Overview of differentiation methods for microglia. 
 
Peripheral blood monocytes have been differentiated to microglia by Leone et al. [4] 
using astrocyte conditioned medium (ACM), granulocyte-monocyte colony stimulating 
factor (GM-CSF) and macrophage colony stimulating factor (M-CSF). They observed 
that addition of LPS returned morphology and levels of substance P to that of 
monocytes. It had been known that co-culture with astrocytes differentiates blood 
monocytes to microglia [8]. Furthermore, it has been repeatedly noted that GM-CSF 
expands primary microglia stronger than M-CSF, for example by Lee et al. [9]. In 
lesions of Multiple Sclerosis and in Alzheimer plaques astrocytes are known to 
produce GM-CSF and regulate microglia proliferation. Primary microglia can be 
differentiated with M-CSF to display a rod shaped morphology [9]. Tsuchiya et al. 
used a modified 5 step protocol for neuronal differentiation to derive microglia from 
ESC [7]. 
Author and year Cell source Differentiation protocol 
Leone 2006 Human peripheral blood 
monocytes (PBMC) 
ACM, GM-CSF, M-CSF 
Davoust 2006 Mouse CD34+/B220+ 
bone marrow cells (BMC) 
M-CSF, ACM 
Servet-Delprat 2002 Flt3L treated non-adherent 
BMC 
Flt3L, ACM 
Tsuchiya 2005 Mouse ESC ITSFn, bFGF, laminin, 
GM-CSF 
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Here, we focused on differentiating microglia from bone marrow. This approach was 
first demonstrated by Servet-Delprat et al. [6]. The group obtained 20% of the cells 
showing microglia-like morphology and displaying microglia markers (CD115+, 
CD11b+, F4/80+, CD80 low, CD86-). In the paper, bone marrow cells from the 
mouse were cultured with FMS-like tyrosine-kinase-3 ligand (Flt3L) for 11 days. 
Afterwards, the supernatant was treated with astrocyte-conditioned medium for 6 
days. The effect of Flt3L on the differentiation of microglia remained unclear because 
supplementation of Flt3L was not controlled.  
A similar protocol was used by Davoust et al. [5]. However much shorter culture 
times and no Flt3L were used to obtain CD11b+, CD45+, MHCII-, B220low, CD34+, 
CD86low cells from mouse bone marrow. Roughly 20% ramified and 50% nestin 
positive cells could be obtained. 
It was intriguing to investigate the impact of Flt3L, as done by Servet-Delprat et al. 
[6], for differentiation of microglia. We therefore wanted to test the combination of 
ACM and Flt3L in a modified protocol and on whole bone marrow. The effect of ACM 
on bone marrow both alone and in combination with the cytokines stem cell factor 
(SCF) [10] and GM-CSF has been reported to be advantageous for microglia 
differentiation. 
Non-adherent bone marrow cells (NA-BMC), defined according to Zhang et al. [11], 
might correspond to a circulating cell population and contain progenitors of many 
different cell types. The capacity of NA-BMC to differentiate to microglia has not been 
investigated until now and we wanted to test their potential for such differentiation. 
Furthermore, the flat influence of in vitro culture time, as well as cell density, on the 
appearance of phagocytic cells plays an important role in differentiation. We also 
modified a macrophage differentiation protocol [12] and supplemented ACM instead 
of M-CSF. 
Co-culture with Living Brain Tissue: We planned to prove in pre-transplantation 
studies that microglia derived from adult stem cells migrate into living brain slices in 
vitro, survive in co-culture and integrate (ramify) (Paper 1 and 2). 
Differentiated microglia, if they are to be used in transplantation, have to be able to 
invade and integrate into brain tissue. It is not granted that the differentiated cells 
survive for a prolonged time in co-culture [13]. There might be rejection by the brain’s 
own microglia [14]. Also, in brain slices it can be studied whether the seeded cells are 
able to perform functions, for example phagocytosis of dead cells [15]. After a while, 
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the seeded cells might cease their activity and integrate into the brain tissue, possibly 
even becoming ramified, similar to the resting state of the brains own microglia [16]. 
Living brain slice cultures (Organotypic hippocampal slice cultures (OHSC)) were first 
established by Stoppini et al. [17]. They were cut from newborn (1-20 days old) mice 
brains and it became quickly apparent that young brains were better suited to cope 
with the injury of cutting the brains into slices. The brain slices reverted to an 
organotypic environment about 9 days after being cut. These brain slices contain 
functional neurons that show electric currents in patch clamp experiments [18]. 
Cultured brain slices from older mice have been reported not to display such 
currents. However, there are also claims that the tissue of brain slices from older 
animals is nontheless alive [19]. We wanted to use living brain slices for migration 
and co-culture experiments accompanying our transplantation experiments. We 
aimed to establish living brain slices of older animals (2-3 months) to have in vitro 
tissue for migration and co-culture comparable to the in vivo transplantation situation.  
Transplantation and Cell Tracking: We planned to transplant and track microglia 
progenitors and MSC (Paper 3 and Additional Data). 
Progenitor cells from the bone marrow might migrate through the blood stream to the 
brain and mature there to microglia [20]. Pronounced migration has been shown in 
certain cases of disease, injury and irradiation of the brain. We therefore planned to 
transplant microglia progenitors systemically in aged mice. As progenitor population 
for transplantation, we chose NA-BMC defined according to Zhang et al. [11]. NA-
BMC contain immature cells, both MSCs but also hematopoietic stem cells (HSC) 
[11].  
MSCs derived from bone marrow should be transplanted to investigate a possible 
regulation of microglia in vivo. With advancing age inflammation, and possibly also 
microglia activity, rise [2]. 
MSCs are known to establish locally a suppressed immune environment and, in large 
numbers, also suppress the immune system organism wide [3, 21]. For example it is 
known that large amounts of fat tissue containing MSCs suppress the immune 
system (WCRF study: Food, Nutrition, Physical Activity, and the Prevention of 
Cancer: a Global Perspective) [22]. The immune suppression effects by MSCs could 
be useful to treat chronic inflammation and autoimmune diseases [23]. 
Stereological Measurements: We planned to quantify changes in microglia 
numbers and activation in response to cell transplantation (Additional Data). We 
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also wanted to quantify changes between young and aged animals. Microglia 
numbers have been reported to rise in female mice in age. This rise might be caused 
by a difference in sex hormones or by general inflammation [24]. Also microglia 
activity was observed to rise in age. This rise in inflammation in various aged tissues 
might be a general phenomenon, often called ‘inflamm-aging’ [2]. Connected to this, 
changes in the microenvironment of several tissues in age are documented. 
 
Fundamentals 
 
Microglia: Microglia have first been described by Del Rio Hortega in 1919 [25]. They 
comprise about 10% of the cell population of the brain [26]. Microglia form the first 
immune defense of the CNS. They perform phagocytosis, act cytotoxic and they 
present antigens. Microglia promote repair after injury [20]. 
 
 
Fig. 1: Microglia in vivo and in vitro. Microglia on the left are stained with Iba-1 in 40 µm thick brain slices. Pictures were taken 
with an Imager A1 (Leica) fluorescence microscope at 630x. The light microscope picture on the right was taken with a DM IL 
(Leica) light microscope (200x). 
 
In general, microglia display a quiescent state in the brain (Fig. 1). Phagocytosis, 
immune response and migration are down-regulated in this state. The microglia are 
ramified and display long and branched processes [27, 28]. 
Inflammation causes microglia activation and a change to an amoeboid morphology. 
Microglia also start to proliferate in reaction to inflammation [29-31]. They migrate 
towards injury, lesions and extracellular debris, for example amyloid- plaques [32].  
The “oxidative burst” is one of the hallmark microglia functions. Microglia perform a 
sudden spike in reactive oxygen species (ROS) levels caused by NADPH oxidase 
activity in response to inflammatory signals. Also, other factors like lysosomal 
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proteases are released. This mechanism is a typical feature of microglia and often 
nicknamed a ‘defense’ response to protect the brain from pathogens [33, 34]. 
Also, microglia play an important role in development and restructuring of neural 
networks. Microglia purge axonal connections [35]. Furthermore, they carry specific 
receptors to detect tagged synapses and remove them [36]. 
During development, microglia also act pro-apoptotic. They remove apoptotic 
neurons and excess connections [37]. 
Origin of Microglia: Microglia might arise from a variety of sources and, despite 
ongoing research, their exact origin is still unknown [38]. Microglia might be of 
neuroectodermal origin, might arise from the vascular adventitia, from HSC intrinsic 
to the central nervous system (CNS), from mesodermal tissue or from circulating 
monocytes. There are reports that primary microglia might home to the brain while 
macrophages do not [39-41]. Therefore it might be of great therapeutical interest to 
identify the originating tissue [38]. However, there have been controversial findings 
regarding directed microglia homing to the brain.   
It has gained a certain acceptance that microglia in the CNS originate from a 
mesodermal progenitor cell during embryogenesis [38]. The CNS is populated by 
these progenitors during development. This takes place on (embryonic) days 10-19 in 
rodents [42]. In man, this colonization takes place between pre-natal months 3-5. 
This early population might arise both from myeloid/mesenchymal origin and from 
fetal macrophages [42]. During later life, additional myeloid progenitors might migrate 
from the bone marrow and invade the brain [20]. In the brain such microglia 
progenitors mature under the influence of factors secreted by astrocytes [8]. In this 
way a slow turnover and replenishment of the microglia population might take place. 
In line with this hypothesis, bone marrow derived microglia can be observed in the 
brain after systemic transplantation [43]. However, while bone marrow (BM) chimeras 
have shown BM derived microglia [44], other findings indicate that without irradiation 
no invasion is observable over a time frame of 1-2 months [45, 46]. Other groups 
could observe migration of intravenously injected hematopoietic stem cells to the 
brain also in non-irradiated mice [47]. They differentiated into microglia and reduce 
infarct size [47]. 
Microglia are capable to proliferate locally and do not necessarily require turnover 
[45, 48]. Others have challenged this view and hypothesized that microglia reach 
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replicative senescence in later life [1]. Furthermore, a loss of function of aged 
microglia has been shown [1, 49-54].  
Microglia in Disease: The general quiescence and graded up-regulation of microglia 
activity might exist to minimize damage to neighboring neural tissue if an immune 
response is initiated [1]. However, if microglia are chronically activated, they act 
cytotoxic and damage cells in the vicinity [55]. Furthermore, microglia might play a 
central role in autoimmune diseases of the CNS. 
Whether microglia act harmful or beneficial in several diseases of the CNS is 
controversial [1, 56, 57]. Both ways of action have been shown in organotypic 
hippocampal slice cultures (OHSC). When microglia were co-cultured with brain 
tissue and treated with lipopolysaccharides (LPS) they acted neurotoxic. Contrarily, if 
they were activated with interleukin 4 (IL-4), the microglia acted neuroprotective in 
co-culture. IL-4 activated microglia up-regulate IGF-1 and down regulate tumor 
necrosis factor alpha (TNF-alpha) [49, 58]. 
The role of microglia seems to depend on distinct sets of surface receptors involved 
in phagocytosis. Receptors recognizing microbes, for example toll like receptors 
(TLR), stimulate a pro-inflammatory response. Microglia activated in this way excrete 
signals associated with inflammation, like tumor necrosis factor (TNF), interleukin IL-
1 and nitric oxide (NO). 
However, if microglia encounter cell debris, receptors recognizing phosphatidylserine 
in apoptotic membranes drive their response. Microglia then perform a ‘silent’ 
phagocytosis [49] and act anti-inflammatory. They show anti-inflammatory cytokines 
like tumor growth factor beta (TGF-beta) and interleukin 10 (IL-10) [59]. 
Also, the loss of function of certain receptors like the triggering receptor (TREM2) or 
DNAX-activating protein 12kDa (DAP12) has been observed to lead to an 
inflammatory neurodegenerative disease later in life [60]. 
Under pathological conditions, for example infection, stroke or neurodegeneration, 
microglia are activated either by direct contact with debris or microbes or by 
cytokines. They migrate to the site of injury. There, the microglia release soluble 
factors, for example cytotoxins, neurotrophins and immunomodulatory molecules. 
They also perform phagocytosis. It becomes apparent that microglia act both 
destructive and also promote repair and regrowth. 
Normally, microglia are ramified. It had long been thought that in this state microglia 
are virtually non-motile. However, in vivo motion picture observations have shown 
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that the processes are in fact continuously forming protrusions and are extending and 
withdrawing [27]. This is reminiscent of extensions in macrophages, which act to 
draw debris to the cell body for phagocytosis. Similar behavior can be observed in 
microglia. It is suspected that the long and branched processes in ramified microglia 
monitor the local neighborhood in this way. In line with the different routes of 
activation through distinct receptors mentioned above, the removal of ‘normal’ debris 
takes place without full activation or strong movement of the cell body. However, if 
microglia are completely activated, they withdraw processes and the whole cell body 
moves to injury or plaques [32]. 
If an injury is caused, for example by facial nerve axotomy, initially local 
neuroinflammation and enhanced proliferation of microglia take place. The 
regeneration of axons is completed over a time frame of about 4 weeks. At this time, 
the microglia activity has already ceased [1]. 
Microglia in Age: The microglia cell population proliferates locally, but might 
additionally be replenished by bone marrow derived progenitors, which migrate over 
the circulation to the brain [1]. 
Resident microglia might reach replicative senescence in old age [1]. In old rats there 
have been indications that proliferation of microglia after injury is stronger than in 
young rats [61]. In vitro, microglia have been reported to undergo telomere 
shortening [62]. In vivo, however, there are reports of stable telomeres and higher 
telomerase activity of microglia after their proliferation had been induced by injury 
[63]. 
This has been linked to the development of neurodegenerative diseases, especially 
Alzheimer, in humans but not in relatively short lived rodents. Over the course of 
such short live spans, a replicative senescence and complementary deterioration of 
the microglia cell population might simply not take place [1]. In brains of older 
humans, deterioration of microglia is observable. In the aging human brain, 
dystrophic microglia are present which show deramification, atrophy, fragmentation 
and swelling [62]. In vitro cultured microglia, if exposed to amyloid protein, are 
degenerating faster [64]. This has also been reported by others, and an overload of 
the intracellular mechanisms to break down digested proteins (proteasome) might be 
one of the possible causes [49, 50, 54]. 
However, even without additional stress by plaque overload or continuous activation, 
there is evidence that a slow deterioration of the microglia cell population in age 
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takes place. Aged microglia have been observed to loose their ability to perform 
normal microglia functions [1, 49-54].  
The function of phagocytic cells of the immune system is known to degrade in age. 
Also, the incidence of autoimmunity in age might result from non-removed debris 
[65]. 
Microglia vs Macrophages: Concerning surface markers, primary microglia and 
macrophages differ only in their levels of expression. Microglia have been reported to 
express cluster of differentiation 11b (CD11b) like macrophages but have only low 
CD45 while macropages show high CD45 levels [66, 67]. Also, low CD68 was 
observed in microglia and high CD68 in macrophages [68]. Furthermore, they differ in 
substance P levels [4]. These different levels of expression correlate with activation 
states. Activated microglia are virtually indistinguishable from macrophages derived 
from monocytes [49]. Also, the overlap in markers between dendritic cells, 
macrophages and microglia has prompted a discussion about their distinction. 
Peripheral blood monocytes and bone marrow can be differentiated to microglia 
using astrocyte-conditioned medium (ACM). ACM not only differentiates microglia but 
also lowers functions like phagocytosis, oxidative burst and migration of microglia. It 
also causes the typical ramification phenotype and the growth of the processes 
visible in ramification. If supplemented with ACM, macrophages show this 
ramification. 
Usually, macrophages are differentiated and expanded using M-CSF [12, 38]. On the 
other hand, ramified microglia can be activated and phenotypically reverted to 
amoeboid or round cells resembling macrophages or monocytes by addition of LPS 
[4].  
It has been proposed that microglia could be immature macrophages that mature if 
exposed to activating signals [38]. Another line of thought suspects that microglia are 
down-regulated, resting macrophages. This is mainly founded on the correlation of 
marker expression and activation states and on the reversibility of activation by 
cytokine supplementation. 
Adult microglia might possess distinct electrophysiological characteristics that differ 
from that of macrophages [69]. These characteristics are also present on a subset of 
bone marrow resident progenitors (Ibid.). 
Furthermore, there are indications that tissue resident macrophages are distinct from 
adult macrophages [70]. It has been proposed that the subpopulation of tissue 
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resident macrophages arise from progenitors prior to vascularization of organs. In the 
adult, macrophages arise mainly from the bone marrow as the major hematopoietic 
tissue. 
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2. Manuscript Overview 
 
Paper 1: “Differentiation of Mouse Bone Marrow derived Stem Cells 
towards Microglia-like Cells.” 
 
Authors: Arnd Hinze, Alexandra Stolzing, Published 
 
Hinze, AH, Stolzing, A: Differentiation of Mouse Bone Marrow derived Stem Cells 
towards Microglia-like Cells. BMC Cell Biology 2011, 12:35 
 
Several protocols for the differentiation of microglia were screened. The differentiated 
cells were compared for marker expression, function (phagocytosis, oxidative burst), 
morphology and migration behaviour. The resulting best protocols are described in 
the publication. Also, the influence of certain cytokines (Flt3L, GM-CSF), time and 
density on the differentiation were investigated.  
 
Arnd Hinze carried out all experiments and wrote the manuscript. Alexandra Stolzing 
designed and coordinated the study and contributed to writing the manuscript. 
 
 
Paper 2: “Microglia differentiation using a culture system for the 
expansion of mice non-adherent bone marrow stem cells.“ 
 
Authors: Arnd Hinze, Alexandra Stolzing, Published 
 
Hinze, AH, Stolzing, A: Microglia differentiation using a culture system for the 
expansion of mice non-adherent bone marrow stem cells. Journal of 
Inflammation 2012, 9:12 
 
Non-adherent bone marrow cells are suspected to correspond to a circulating cell 
population. They might, therefore, harbor microglia progenitor cells. The cell culture 
of non-adherent bone marrow cells is further characterized in the paper and their 
differentiation capacity to microglia was tested. 
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Arnd Hinze carried out all experiments and wrote the manuscript. Alexandra Stolzing 
designed and coordinated the study and contributed to writing the manuscript. 
 
 
Paper 3: “To Migrate or not to Migrate – Microglia and Cell Migration 
to and from the Brain.” 
 
Authors: Arnd Hinze, Alexandra Stolzing, Submitted to Journal of Inflammation, 
10/2012 
 
Migration of cells into the brain is subject to many conditions, age and diseases. The 
review summarizes conditions under which cells migrate across the BBB and into the 
brain. It also delves into conditions that influence the success of cell therapies 
directed at the brain. 
 
Arnd Hinze designed and wrote the manuscript. Alexandra Stolzing contributed to 
writing the manuscript. 
 
 
 
 
 
3. PAPER 1: “Differentiation of Mouse Bone Marrow derived Stem Cells towards Microglia-like Cells” 13 
3. Paper 1: “Differentiation of Mouse Bone Marrow derived Stem 
Cells towards Microglia-like Cells.” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. PAPER 1: “Differentiation of Mouse Bone Marrow derived Stem Cells towards Microglia-like Cells” 14 
Differentiation of mouse bone marrow derived stem cells toward microglia-
like cells 
 
Arnd Hinze, Alexandra Stolzing 
Fraunhofer Institute for Cell Therapy and Immunology (IZI), Perlickstrasse 1, 04103 
Leipzig, Germany 
 
Corresponding author 
Alexandra Stolzing 
Fraunhofer Institute for Cell Therapy and Immunology 
Perlickstrasse 1 
04301 Leipzig, Germany 
alexandra.stolzing@izi.fraunhofer.de 
Tel. 0049-341355363405 
 
Running title: Microglia from stem cells 
 
Key words: bone marrow stem cells, microglia, Flt3L, GM-CSF, neurodegeneration, 
differentiation 
 
 
 
 
 
 
 
 
3. PAPER 1: “Differentiation of Mouse Bone Marrow derived Stem Cells towards Microglia-like Cells” 15 
Abstract 
Background: Microglia, the macrophages of the brain, have been implicated in the causes of 
neurodegenerative diseases and display a loss of function during age. Also, recent studies 
emphasized the heterogeneity of microglia in the brain and linked it to the potential of 
microglia to induce tolerance or immune reaction. It is therefore of great interest to investigate 
the differentiation of microglia for development of actual immune function. We differentiated 
here microglia from bone marrow stem cells (BM). Furthermore we looked at the effects of 
FMS-like tyrosine-kinase-3 ligand (Flt3L), astrocyte conditioned medium (ACM) and GM-
CSF on the differentiation to microglia-like cells.  
Methods: We assessed in vitro derived microglia differentiation by marker expression 
(CD11b/CD45, F4/80), but also for the first time for functional performance (phagocytosis, 
oxidative burst) and in situ migration into living brain tissue. Integration, survival and 
migration were assessed in organotypic brain slices. 
Results: The cells differentiated from mouse BM show function, markers and morphology of 
primary microglia and they migrate into living brain tissue. Flt3L displays a negative effect on 
differentiation while GM-CSF enhances differentiation.  
Conclusion: We conclude that in vitro derived microglia are the phenotypical and functional 
equivalents to primary microglia and could be used in a cell therapy. 
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Background 
Microglia comprise about 10% of the cell population of the brain and form the main first 
immune defense of the CNS. They are phagocytic, cytotoxic, present antigens and promote 
repair after injury [1]. Primary microglia differ from other blood macrophages in the 
expression levels of markers like CD11b/CD45low/high [2], CD68 low/high [3] and 
substance P levels [4]. Because of the overlap in markers there is an ongoing discussion about 
the distinction between dendritic cells, macrophages and microglia. The microglia cell 
population partially shows dendritic cell phenotypes [5].  This heterogeneity has been linked 
to activation states of microglia and the potential to induce tolerance or immune reactions [6, 
7]. It is therefore of great interest to investigate the differentiation of microglia from bone 
marrow – especially in view of possible subpopulations acting tolerance inducing which 
might be identified by expression of antigens implied in tolerance [6] and by tests of immune 
function in vitro.  
Microglia in the brain display normally a quiescent state in which phagocytosis, immune 
response and migration are down-regulated and the microglia show a ramified form with long 
processes [8]. Microglia react to inflammation by turning to an activated state and taking on 
an amoeboid morphology [9]. They migrate towards injury, lesions and extracellular debris 
such as amyloid- plaques [10]. An important function of microglia is the "oxidative burst" – 
a sudden spike in reactive oxygen species (ROS) levels generated by the stimulation of the 
NADPH oxidase. This ROS production is accompanied by the release of other factors, 
including lysosomal proteases. This mechanism, often interpreted as a ‘defense’ response that 
can protect the brain from pathogens is a typical feature of microglia [11, 12]. 
Microglia are thought to originate from the yolc sac during embryogenesis [13]. They are 
thought to be replenished during life mainly by local proliferation. The replenishment by 
progenitor cells from the bone marrow is controversial [1, 13, 14]. Bone marrow derived 
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microglia can be observed in the brain after systemic transplantation [15]. While BM 
chimeras have shown BM derived microglia [16], other findings indicate that without 
irradiation no invasion is observable in the time frame of 1-2 months [17, 18]. But also in 
transplantations without irradiation intravenously injected hematopoietic stem cells have been 
observed to migrate to the brain, differentiate into microglia and reduce infarct size [19].  
The maturation of progenitors to microglia occurs under the influence of factors secreted by 
astrocytes [20]. Both local and peripheral replenishment seem not to suffice to prevent the 
slow deterioration of the microglia cell population and function in age [21, 22]. In human 
Alzheimer patients microglia associated with tau were found to be fragmented and this 
dystrophy might preceed neurodegeneration [23]. In old rats there have been indications that 
proliferation of microglia after injury is stronger than in young rats [24]. In vitro, microglia 
have been reported to undergo telomere shortening [25] and aged microglia have been 
observed to loose their ability to perform normal microglia functions [21, 22, 26-30]. All of 
these findings support the hypothesis of a slow deterioration of microglia as a contribution to 
the onset of neurodegeneration [22, 23]. Observations that amyloid beta plaques were not 
colocalized with activated microglia might indicate that they are not responsible for a chronic 
activation [23]. Also, anti-inflammatory drugs have not shown a clear enhancement of 
Alzheimer condition [31, 32]. Therefore, chronic activation might be a later occurring step in 
neurodegenerative diseases.  
Microglia have been differentiated in vitro from peripheral blood monocytes [4, 20] and from 
embryonic stem cells [33]. Here, we are focusing on differentiating microglia from bone 
marrow. This approach was first demonstrated by [34] who obtained a 20% occurrence in 
microglia-like morphology and marker expression (CD115+, CD11b+, F4/80+, CD80 low, 
CD86-) after culturing mouse BM cells in Flt3L for 11 days and then treating the supernatant 
with astrocyte conditioned medium for 6 days. However, since the use of Flt3L was not 
controlled in that protocol, its role as a factor in microglia differentiation remained unclear. 
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Davoust et al. [35] used a similar protocol but much shorter culture times, and no Flt3L to 
obtain CD11b +, CD45 + , MHCII - , B220 low, CD34+, CD86 low cells from mouse BM 
(the percentage yield is not given). The success of microglia cell differentiation has been 
mostly judged by measurement of marker expression and morphology of the differentiated 
cells. It was unclear to what extent in vitro derived microglia share the functional capacities of 
microglia in vivo. To address this question, we followed the protocol of Servet-Delprat et al. 
[34] (with and without Flt3L), measured phagocytosis and oxidative burst as hallmarks of 
microglia function and tested the ability to survive and migrate in brain tissue. 
 
Results 
Surface marker expression 
Untreated bone marrow cells showed significantly increased CD11b/CD45 expression after 
17 days. The same was seen in cultures treated with ACM/GM-CSF. Non adherent BM cells 
treated with ACM/GM-CSF and whole bone marrow cultivated for 17 days are observed in 
the same region in the flow cytometry plots as primary microglia. Flt3L has an adverse effect 
on differentiation, leading to low levels of CD11b/CD45 positive cells in all Flt3L 
supplemented samples. 
The frequency of F4/80+ cells increased significantly in whole bone marrow already after 7 
days and also after 17 days compared to fresh bone marrow. The supplementation of Flt3L or  
Flt3L/ACM/GM-CSF resulted in significantly lower F4/80+ cell numbers while the addition 
of only ACM/GM-CSF yielded high numbers of F4/80+ cells very similar to the 
CD11b/CD45 cell populations (Fig. 1, table 1). 
 
Time course of marker expression 
The frequency of CD11b+/CD45+ and F4/80+ cells in whole bone marrow rose steadily and 
significantly with culture time (Fig. 2, table 1). The additional supplementation of 
ACM/GMCSF to the non-adherent BM cells increased CD11b+/CD45+ and F4/80+ cells over 
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time, however the increase was significantly slower and only reached the same level as un-
supplemented bone marrow at day17. The supplementation of Flt3L resulted in a lower 
frequency of CD11b+/CD45+ and also F4/80+ (Fig. 2, table 1). The addition of 
ACM/GMCSF increased the medians of CD11b expression significantly after 10 days (Fig. 2, 
table 1). 
 
Phagocytic activity and oxidative burst 
Whole bone marrow cultured over a period of 7, 10 or 17 days showed a constant significant 
higher percentage of phagocytic cells compared to fresh bone marrow (Fig. 3A). 
Supplementation with ACM/GM-CSF increased the number of phagocytotic cells 
significantly compared to un-supplemented bone marrow at day 17. Flt3L supplementation 
inhibited the differentiation towards phagocyting microglia significantly even when 
ACM/GM-CSF was added. We observed the same changes in the amount of microglia 
performing oxidative burst (Fig.3b), however the differences were less pronounced. 
 
Cell morphology 
Primary microglia show long processes and rod shaped cells (Fig. 4A). Un-supplemented 
bone marrow cells had mixed morphologies during the whole cultivation time (Fig. 4B-E). 
The cells supplemented with ACM/GM-CSF are homogenous and show strong ramification 
(Fig. 4G). Cells treated with Flt3L alone or in presence of Flt3L and ACM/GM-CSF both 
have a more fibroblastic morphology with no resemblance to microglia (Fig. 4H, 4I). 
 
Migration in organotypic brain slices 
Whole brain slices were cultured for 10 days to minimize surface damage before 
differentiated microglia pre-labeled with 3,3'-dioctadecyloxacarbocyanine perchlorate (DiO) 
were added on top of the brain slices. The slice was counterstained with propidium iodide (PI) 
to visualize dead cells. Reconstructed confocal pictures were either top-down or showing a 
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side view of the slice. Microglia were observed over a period of 10 days and found to survive 
and proliferate (Fig. 5A-C, dead cells deliberately included for reference). Over the course of 
3 days ACM/GM-CSF supplemented BMC migrated into the surface of the brain slices as 
deep as 50m (Fig. 5D-F). Cells of all protocols migrated up to 30m into the slice after 10 
days, while dead cells stayed on top of the tissue (Fig. 6A, 6B, 6C, 6D). Several cells 
migrated up to 120m (scan depth of confocal microscope was 160m). Cells supplemented 
with Flt3L have the same fibroblastic morphology as in the in vitro cultures (Fig. 6B) while 
additional supplementation with ACM/GM-CSF resulted in round and amoeboid cells as well 
as fibroblastic cells (Fig. 6C). Cells supplemented only with ACM/GM-CSF showed almost 
exclusively round cell morphology (Fig. 6D). Cells of whole bone marrow were round but 
bigger than the ACM/GM-CSF supplemented cells after 7 days and did not migrate more than 
30m into the surface of the brain tissue (Fig. 6A). 
 
Discussion 
We investigated here the differentiation and function of microglia from bone marrow (BM) 
stem cells using ACM and GM-CSF with and without Flt3L. We used GM-CSF as opposed to 
M-CSF used by Davoust et al. [35] as this is reported to expand primary microglia more 
successfully than M-CSF [40, 41]. Primary microglia have been characterized as 
CD11b+/CD45low and have been distinguished from primary macrophages by their CD45 
expression level [2]. The in vitro differentiated microglia derived here generally show similar 
marker expression levels as primary microglia. It is known that ACM treatment of BM cells 
can produce cells with markers for microglia [34]. 
However, such cells have not been further characterized with regards to phagocytotic 
capacity, migration behavior inside the brain or tested for the microglia-typical oxidative 
burst. Here we demonstrate that BMC cultured in the presence of ACM, GM-CSF show 
microglia typical phagocytosis and oxidative burst activity. The cells also had long and 
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branched processes similar to primary microglia. Flt3L supplementation diminished the 
functional markers and microglia like morphology. Thus, among the parameters tested here, 
the ‘optimal’ protocol for in vitro differentiation of microglia relies on ACM, GM-CSF 
without Flt3L. 
Interestingly, we find that even un-supplemented BM contains a subpopulation positive for 
microglia markers (CD11b/CD45, F4/80) and that this population is more dominant after 17 
days differentiation. However, we find that microglia-like cells derived from BM without any 
supplementation only display low phagocytosis and oxidative burst levels compared to 
ACM/GM-CSF supplemented cells. 
Generally, un-supplemented bone marrow cultures show mixed cell morphologies whereas 
supplemented cultures are more likely to display homogeneous branched morphologies. 
Flt3L has been used for the sequential differentiation of BM cells presumably because it 
improves hematopoietic stem cell (HSC) survival in vitro [34] and in vivo [42]. Servet-
Delprat et al. only looked at Fl3L supplemented cells and did not consider un-supplemented 
cells. The group estimated 20% microglia from the number of ramified cells which is 
confirmed by our results for ACM, GM-CSF, Flt3L supplemented cells. However, much 
higher microglia ‘yield’ can be obtained in the absence of Flt3L. In fact, we demonstrate that 
supplementation with Flt3L diminishes microglia differentiation: where Flt3L is added by 
itself of in combination with ACM, GM-CSF, the number of cells showing microglia markers, 
as well as the capacity for brain migration, phacocytosis and oxidative burst decreases. 
The differentiation protocols investigated here rely on using the supernatant at day 11 to 
select for non-adherent HSC which is then cultured in the presence of ACM for another 6 
days. The tactic here is to first obtain a relatively pure HSC population which then 
differentiates in part into adherent microglia. Flt3L has been shown to expand HSC, 
transiently increase adhesion of HSC in culture and might play a role in mobilization of HSC 
to the blood stream [43] (Supplementary figure 2). Therefore the amount of microglia 
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progenitor cells in the supernatant of the 11 day bone marrow culture might be decreased or 
the differentiation might be delayed. In addition Flt3L combined with GM-CSF has been 
shown to enhance dendritic cell differentiation [44]. This fact is supported by work with Flt3L 
knockout mice where levels of dendritic cells are increased and numbers of myloid cells, the 
progenitors for microglia, are decreased [45]. These factors may explain why Flt3L 
supplementation yields a lower count in functional in vitro-derived microglia. 
The microglia cell population is known to be heterogeneous and to overlap with dendritic cell 
like populations in the brain [46]. The various procedures employed for microglia 
differentiation might result in distinct subpopulations or activation states. The choice of the 
protocol might have a large impact on the effect transplanted cells will have in vivo. This is 
especially important because different subsets of microglia have been linked to induction of 
tolerance or immune reaction [6]. 
The expression of Tmem176b and TREM2 has been associated with tolerance of microglia 
[6]. Also, the loss of function of certain receptors like the triggering receptor (TREM2) or 
DNAX-activating protein 12kDa (DAP12) has been observed to lead to an inflammatory 
neurodegenerative disease later in life [47]. Differentiated microglia carrying such markers 
could be beneficial to reduce reaction to transplants [48] or to treat autoimmune 
inflammation, for example in acute experimental autoimmune encephalomyelitis [5, 49].  
Transplantation of human microglia in ischemic brains modulated inflammation and reduced 
neuronal apoptosis [50]. Microglia provided neuroprotection in hippocampal slice cultures 
while lipopolysaccharide-stimulated microglia did not [51]. 
However, differentiation of immunogenic dendritic like cells from bone marrow might result 
in immune reaction if used in transplantation. In the current study, microglia were 
differentiated using ACM and GM-CSF. There is evidence that cells showing an immature 
dendritic phenotype can differentiate from microglia under the influence of GM-CSF [46]. At 
the same time, dendritic cells can be differentiated to microglia like cells which inhibit T cell 
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proliferation induced by mature dendritic cells [52]. Dendritic cells can act both tolerogenic or 
immunogenic, depending on their maturation state [48].  
In co-cultures with organotypic brain slices the differentiated microglia survived and 
proliferated for at least 10 days. It is known that the majority of primary microglia or BV2 
cells just migrate over the surface layer of brain tissues under non-inflammatory conditions 
[53, 54] while a subpopulation migrates into the tissue. Directed migration towards sites of 
injury induced by NMDA on the surface of brain slice cultures has been observed for primary 
microglia [54]. The damaged surface of the brain slice cultures even attracts slice internal 
microglia which showed directed migration to the surface [53]. This is supported by our 
results: Most cells migrate into the brain slice tissue superficially, while in vitro derived 
(ACM/GM-CSF, but without Flt3L) microglia migrated deepest into the tissue and showed 
both amoeboid and rounded morphologies suggesting an activated state. 
 
Conclusion 
The in vitro differentiated cells correspond in phenotype and function to primary microglia.  
If neurodegenerative diseases occur in part due to a deterioration of the microglia cell 
population or function with age, functional microglia supplementation could have beneficial 
effects. For example, injection of primary microglia into the brain of rats led to an increased 
amyloid beta clearance [55] Furthermore, the suspected ability of microglia precursors to 
cross the blood brain barrier and to seek out sites of neuroinflamation makes them potentially 
useful drug delivery vehicles [56]. In vitro derived microglia will need to demonstrate the 
functional capacity of ‘real’ microglia cells and this research makes some contributions 
towards this aim. Also, the differentiated microglia could now be screened for markers of 
tolerance inducing microglia subsets and for the actual induction of tolerance in vitro [6]. 
 
Methods 
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Animals 
C57BL/6 mice from the MEZ of the University of Leipzig and Charles River (Sulzfeld, 
Germany) were used as sources for bone marrow, primary microglia and organotypic brain 
slices in accordance with local animal ethics permissions. 
 
Isolation of bone marrow and cell culture 
Bone marrow was obtained by centrifugation of femurae and tibiae. Isolated bone marrow 
cells were cultured at a density of 107 cells in a 60mm petri dish in 5ml of Dulbecco minimal 
essential medium (DMEM)/low glucose (Hyclone Laboratories Inc.) supplemented 10% fetal 
calf serum (FCS -Invitrogen) and 100 units/ml Penicillin, 100 g/ml Streptomycin. 
 
Astrocyte conditioned medium 
Astrocyte conditioned medium was produced by incubating medium (DMEM/10% FCS) 24h 
with primary astrocyte cultures [16]. 
 
Isolation of primary microglia 
Primary microglia were isolated from brains of 1-3 day old mice. The meninges was removed 
and the whole brain was titurated in DMEM/10% FCS and Pen/Strep. The resulting cell and 
tissue suspension of 3 brains was cultured in a poly L-lysine coated culture flask. After 24h 
the supernatant was removed from the cell culture and new medium added. After 7 days 50% 
of culture medium was changed. At 14 days microglia were removed by gentle shaking [36]. 
 
Differentiation towards microglia-like cells 
Whole BMC: Whole bone marrow (107 cells) was cultivated over the time periods of 7, 10 
and 17 days in 10ml DMEM/10% FCS in a 60mm petri dish. When cells were cultured for 
longer than 10 days 50% of medium was replaced at day 10 (Supplementary figure 1). BMC 
+ ACM/GM-CSF: 107 cells were cultured for 11 days in a 90mm petri dish in DMEM/10% 
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FCS. After 11 days, non adherent cells from 2 petri dishes were flushed off. These cells were 
transferred to a new 60mm petri dish and cultured for additional 6 days in DMEM/10% FCS, 
50% ACM, 20ng/ml GM-CSF (Supplementary figure 1). BMC + Flt3L/ACM/GM-CSF: 107 
cells were cultured for 11 days in a 90mm petri dish in DMEM/10% FCS/5ng/ml Flt3L. The 
non adherent cells of day 11 were transferred to a 60mm petri dish. Afterwards the cells were 
cultured in DMEM/10% FCS, 50% ACM, 20ng/ml GMCSF for 6 days. BMC + Flt3L: 107 
cells were cultured for 11 days in a 90mm petri dish in DMEM/10% FCS/5ng/ml Flt3L. After 
transferring the non adherent cells of day 11 were to a 60mm petri dish they were cultured in 
DMEM/10% FCS for 6 days (Supplementary figure 1). 
 
Flow cytometry 
The differentiated cells were tested for the markers F4/80, CD11b, CD45 and CD11b/CD45 
double expression. The cells were trypsinized, centrifuged at 300g for 5min and fixed in 4% 
paraformaldehyde. They were washed with phosphate buffered saline (PBS). Afterwards cells 
were incubated for 2h at 4°C with CD11b (1:250) or F4/80 (1:250) antibody (both Alexa 488 
labeled, eBioscience) or with CD45 (1:100) antibody (PE labeled, eBioscience). The 
incubated cells were washed again and fluorescence measured with a Beckmann Coulter FC 
500. 
 
Phagocytosis 
Phagocytic activity of the differentiated cells was measured by the uptake of fluorescent beads 
(Sigma, 2m yellow green fluorescent). In a first step samples of 3*105 cells were activated 
with phorbol myristic acid (PMA) (0.1M) for 15min at 37°C [37]. Afterwards they were 
incubated in 50l DMEM/10% FCS together with 50l opsonized (FCS) beads for 48h at 
37°C, 5% CO2. The uptake of fluorescent beads was observed qualitatively in a Zeiss Axio 
Observer fluorescence microscope. For quantitative assessment the cells were trypsinized and 
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resuspended in PBS (Invitrogen). Cells were repeatedly washed and fluorescence was 
measured in a Beckmann Coulter FC 500. 
 
Oxidative burst 
Nitro Blue Tetrazolium (NBT): 104 cells were seeded on cover slips. They were incubated 
with 30l 1mg/ml NBT and 100 nM PMA for 45 min at 37°C and 5% CO2 [38]. Light 
microscope pictures were taken with a Leica DM IL (Leica) using the LAZ EZ 1.4.0 software 
(Leica). Pictures were brightness and contrast adjusted with GIMP 2.4.5 and power point 
(Microsoft). 
Dihydrorhodamine 123 (DHR123): 3*105 Cells were incubated in PBS for 15min at 37°C 
with 0.1M PMA. Controls were incubated without PMA. Afterwards 50M DHR123 
(Invitrogen) was added and the cells were incubated for additional 15min at 37°C. The cells 
were fixed with 4% PFA and fluorescence was measured in a Beckmann Coulter FC 500. 
 
Cell Morphology 
A DM IL (Leica) and the LAZ EZ 1.4.0 software (Leica) was used to take light microscopic 
pictures. 
 
Brain slice cultures 
2-3 month old C57BL/6 mice were killed by cervical dislocation. The brain was isolated and 
cut with a Leica VT 1000 S vibratome in 350m slices in cold preparation medium (HBSS 
and 10% FCS (Invitrogen)). The slices were transferred to an insert (Millicell CM 0.4 m, 
Millipore) and cultivated with brain slice culture medium (50% DMEM/high glucose 
(HyClone Laboratories Inc.), 25% Horse Serum (Invitrogen), 25% HBSS (Invitrogen), 1 
g/ml insulin, 100 units/ml penicillin, 100 g/ml streptomycin). Medium was changed every 
2-3 days. The brain slices were cultured for 9 days before cells were seeded on them [39]. 
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Survival and migration in brain slice cultures 
Differentiated cells were labeled for 20min with DIO (Invitrogen). They were added to the top 
of the brain slices. The viability of brain slice cultures was checked by performing PI staining. 
The survival of seeded cells was checked by adding 5g/ml propidium iodide in the medium, 
washing and scanning the slices with a confocal microscope TCS SP2 (Leica Microsystems) 
using the accompanying software LCS 2.6 (Leica Microsystems). The slices were scanned 
after 10 days of co-culture to a depth of 160 m. Images were contrast and brightness adjusted 
with GIMP 2.4.5 and power point (Microsoft). 
 
Statistical Analysis 
All data are presented as means ± SE. Statistic analysis were made using SigmaPlot 
10.0/SigmaStat 3.5 software (SYSTAT, Erkrath, Germany). 
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Figure legends 
 
Figure 1: (A) Flow cytometric analysis of differentiated cells concerning their CD11b/CD45 
expression (n=3). Representative scatter plots of CD11b/CD45 labeled differentiated cells and 
primary microglia, fresh bone marrow and an isotype control. 
(B) Flow cytometric analysis of differentiated cells concerning their F4/80 expression (n=3). 
Representative histogram plots of F4/80 labeled differentiated cells and primary microglia, 
fresh bone marrow. Isotype control gray, F4/80 labeled cells black. *** = P<0.001, ** = 
P<0.01, * = P<0.05. 
 
Figure 2: Time course of CD11b/CD45 and F4/80 expression of untreated and cytokine 
treated BMC (n=3). Time course of CD11b and F4/80 medians. Significant changes are 
denoted with respect to freshly isolated BMC on day 0. *** = P<0.001, ** = P<0.01, * = 
P<0.05. 
 
Figure 3: (A) Phagocytosis of differentiated cells and fluorescence microscope picture of 
phagocytosis of non adherent BM cells differentiated with ACM/GM-CSF (n=3). Arrows 
indicate the same cell in bright field and fluorescence picture. Fluorescence images were 
taken with a Zeiss Axio Observer at 200x (left) and 400x (right) magnification. 
(B) Oxidative burst of differentiated cells, representative histogram plot of inactive (open 
histogram) and PMA activated (red histogram) cells (n=3). The shift between un-treated and 
PMA treated microglia was measured as quotient between medians of treated and untreated 
cells (Fluorescence signal noise ratio – FSN). Cells with no shift are based at 1 and higher 
numbers represent cell populations which did show ROS production. Light microscope 
picture of NBT reduction of non adherent BM cells supplemented with ACM/GM-CSF. 
Arrows indicate one cell with dark blue NBT precipitate and one cell without precipitate. The 
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picture was taken with a Leica DM IL at 20x magnification. *** = P<0.001, ** = P<0.01, * = 
P<0.05. 
 
Figure 4: Representative light microscope pictures of differentiated cells. Images were 
taken with a Leica DM IL at 200x magnification. BMC: Whole bone marrow cells. 
Fluorescence picture of an Iba-1 stained microglia in a brain slice (B) was taken with an Axio 
Imager A1 (Zeiss) at 63x magnification. 
 
Figure 5: Coculture with living brain slices. Differentiated ACM/GM-CSF treated BMC 
were labeled with DIO and seeded on brain slices on day 9. Counterstaining with propidium 
iodide was used to assess cell survival. After 1, 2 , 3, 6 and 10 days slices were scanned with a 
Leica Microsystems TCS SP2 confocal microscope to assess survival of seeded cells and their 
migration into the tissue. Arrows indicate single cells that have already migrated through the 
surface after 2 days. Magnification was 100x and scanning depth was 160 m. 
 
Figure 6: Differentiated cells of all protocols were labeled with DIO and seeded on brain 
slices on day 9. After 10 days coculture slices were propidium iodide stained and scanned 
with a Leica Microsystems TCS SP2 confocal microscope to measure cell survival and their 
migration. Arrows indicate several cells that have migrated deeper into the brain tissue. The 
images were taken at 100x magnification and the brain slices were scanned to a depth of  
160 m. 
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Tables 
Table 1: Flow cytometric analysis of the cells differentiated and analyzed for microglia 
specific markers. 
 
Protocol Suppleme
ntation 
 
CD11b 
percent  
 
CD11b 
median 
 
F4/80 
percent 
 
F4/80 
median  
CD11b/CD4
5 percent 
 
Cells in 
microglia 
gate 
BM 0 
days 
 20 
+/-9.5 
2 
+/-0.7 
2.3 
+/-0.1 
1.2 
+/-0.1 
20 
+/-9.5 
6,7 
+/-3,6 
BM 7 
days 
 51,2 
+/-15,5 
7,8 
+/-3,5 
55,9 
+/-5,3 
4,4 
+/-0,6 
54,7 
+/-15,0 
54 
+/-19,7 
BM 10 
days 
 67,3 
+/-2,8 
8,8 
+/-1,5 
59,8 
+/-3,3 
4,3 
+/-0,3 
72,8 
+/-2,9 
70,3 
+/-4,1 
BM 17 
days 
 68,4 
+/-0,6 
13,8 
+/-0,4 
64,5 
+-0,6 
3,6 
+/-0,1 
70 
+/-0,5 
84,2 
+/-0,5 
Supernat
ant of BM 
culture on 
day 11 
 71,7 
+/-3,6 
9,5 
+/-1,3 
40,5 
+/-5,1 
2,7 
+/-0,4 
71,7 
+/-3,6 
62,7 
+/-6,5 
Supernat
ant of BM 
culture on 
day 11 
Flt3L 35,8 
+/-12,9 
3,6 
+/-2,1 
6,8 
+/-
1,3% 
1 
+/-0,2 
35,8 
+/-12,9 
20,1 
+/-18,8 
Protocol 2  ACM/GM
-CSF 
85,6 
+/-1,5 
23,3 
+/-2,9 
66,4 
+/-1,7 
3 
+/-0,3 
89,1 
+/-1,5 
90 
+/-1,7 
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Protocol 3 Flt3L/AC
M/GM-
CSF 
39,1 
+/-8,1 
2 
+/-0,3 
18,8 
+/-3,1 
1,3 
+/-0,2 
46,6 
+/-8,0 
9,9 
+/-2,7 
Protocol 4  Flt3L 8,2 
+/-4,1 
1 
+/-0,0 
10,7 
+/-5,1 
1,1 
+/-0,1 
15,5 
+/-4,1 
5,1 
+/-0,5 
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Microglia differentiation using a culture system for the expansion of 
mice non-adherent bone marrow stem cells 
Arnd Hinze, Alexandra Stolzing  
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Introduction: Studying primary adult microglia is hampered because of the difficult 
isolation procedure and the low cell yield. We therefore established a differentiation 
protocol using a culture system developed for the expansion of non-adherent bone 
marrow cells. Methods: Non-adherent bone marrow derived stem cells (NA-BMC) 
are derived by selective adhesion (‘preplating’) and are non adhesive adult stem 
cells. We investigated the changes in bone marrow cell populations by this repeated 
selective adhesion and compared the potential of the derived cells to differentiate 
towards microglia. Cells were differentiated with astrocyte conditioned medium 
(ACM) and granulocyte-monocyte colony stimulating factor (GM-CSF). Results: NA-
BMC cultures show a steep raise in the fraction of stem cells during the cultivation 
time and the differentiation potential is of the same quality as established protocols. 
Around 70% of the cells are microglia defined as being positive for CD11b/CD45 and 
show phagocytosis activity and oxidative bursts. Conclusion: The non-adherent cell 
system has the advantage that is produces stem cell progenitors during expansion 
and provides good microglial differentiation.  
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Introduction 
Microglia are the immune-cells of the brain. They react to inflammatory signals, seek 
out and phagocytize debris and promote repair and regeneration by excreting growth 
factors [1]. Microglia might, however, promote neurodegenerative diseases like 
Alzheimer or multiple sclerosis by dysregulation and overreaction to chronic 
inflammatory signals. A suspected loss of their ability to function as debris clearing 
cells with age or an insufficient renewal of their population in age was described [1]. 
The role microglia play in these diseases and the possible changes the microglia 
population undergoes with age are the key to understand and combat the causes of 
neurodegeneration. 
Studies of microglia in vitro use mostly primary microglia from mouse or rat embryos. 
Human microglia are difficult to obtain and they are often derived from post-mortem 
donors, posing some extra difficulties concerning cell viability. To study the role of 
microglia in neurodegeneration it is however necessary to work with adult material as 
the onset of the disease is age-dependent. The alternative is to use blood or bone 
marrow derived monocytes to derive microglia [2]. The in vitro generation of microglia 
may chart the way towards new therapeutic strategies using adult stem cells or to 
study the function of microglia generated from individuals of all ages and from 
diseased background to better understand their role in neurodegeneration.  
Non-adherent bone marrow cells (NA-BMCs) harbor cells of the hematopoietic 
lineage [3]. NA-BMCs are known to rescue lethally irradiated mice [3, 4]. Their 
potential to give rise to microglia could be of use in cell-based therapies of the central 
nervous system (CNS) [1]. Non-adherent mesenchymal stem cells (MSC) are present 
in NA-BMC cultures as well [3]. They give rise to fibroblastic, osteoblastic, 
chondrocytic and adipocytic lineages. They have been found to colonize various 
tissues like bone marrow, spleen, intestine, kidney and liver.  
NA-BMCs might correspond to a naturally circulating population of cells [3], which 
carries progenitors of several somatic cell types. In line with this, cells residing in the 
blood have been differentiated to various cell types [5] and it is known that peripheral 
blood monocytes can be differentiated to microglia in vitro [6]. Also, fibroblast-like 
cells are mobilized from the bone marrow by various effects like cytokines, hypoxia 
and skin damage [7-10]. 
MSC are known to regulate microglia and other immune cells [11-14]. Bone marrow 
derived mesenchymal stem cells transplanted into the brain result in a reduction of 
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amyloid-ß plaques [15] - possibly by activation of resident microglia to an amoeboid 
and phagocytic state. Transplanted MSC have positive effects in neurodegeneration 
by regulation of the microenvironment and by cell fusion [16, 17]. MSC regulate 
activation of microglia in co-culture [18, 19]. These findings suggest that inclusion of 
MSC in a microglia cell population might even be beneficial. 
To solve the problem of microglia availability and viability we explore here the 
improved generation of microglia cells from adult stem cells. We designed two new 
protocols to differentiate microglia from so called non-adherent bone marrow cells 
(NA-BMCs) (Fig. 1), which can be expanded efficiently in vitro in suspension cultures 
without loss of stem cell properties. They correspond to a classical method for 
macrophage differentiation (Protocol 2) and a culture system originally developed for 
expansion of stem cells (Protocol 1) (Fig. 1). The different stages and gradual 
changes during this expansion protocol are poorly investigated. The composition of 
these cell cultures over time, the changes in colony forming units (CFU-f) and the 
capacity to differentiate to microglia have not been characterized in the past. Special 
focus was on the functional characterization of the microglia derived by this protocol.  
 
Materials and Methods 
Animals 
Animals used for the experiments were C57BL/6 from the MEZ Leipzig and Charles 
River (Sulzfeld, Germany). They were handled in accordance to local animal ethics 
regulations.  
Bone marrow isolation and culture of NA-BMC 
Femurae and tibiae of 2-3 month old C57BL/6 mice were isolated, opened and 
centrifuged to obtain bone marrow. 107 bone marrow cells were cultivated for 24h in 
a 60mm petri dish and in 10ml Dulbecco’s modified eagle medium (low glucose) 
(DMEM, Hyclone Laboratories Inc.), supplemented with 10% fetal calf serum (FCS) 
(Invitrogen), 10-8 M dexamethasone and 100 units/ml Penicillin/Streptomycin 
(Invitrogen). After 24h the non-adherent cells were flushed off and transferred to a 
new dish (protocol 2; Fig. 1). This 24h adhesion period was repeated 4 times to 
derive NA-BMC cells (protocol 1; Fig. 1).   
CFU-f 
The non-adherent cells of day 1 (classical replating protocol to derive macrophages, 
protocol 2) and NA-BMCs from day 4 (protocol 1) were resuspended in 5ml 
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osteogenic medium (DMEM, 10% FCS, 10-8 M dexamethasone, 50µg/ml ascorbic 
acid) in a 60mm dish. Every 3 days, the medium was changed. After 10 days, the 
cells were fixed with cold ethanol and alkaline phosphatase (ALP), calcium (Alizarin 
red), collagen (Sirius red) and methylene blue (total colonies) staining performed. 
The colony numbers were determined using the program ImageJ. 
ALP staining 
The cells in 60mm petri dishes were fixed with cold ethanol for 15min. They were 
washed with tap water. Tris (200mM, pH 8.5) was mixed with naphthol phosphate 
ASBI (50µg/ml) and fast red (1mg/ml) (Fast red was always mixed fresh). 5ml of the 
mixture was added to petri dishes. The dishes were shaken for 2h at room 
temperature. Afterwards they were washed with tap water and allowed to dry. 
Photographs of the dishes were taken and colony numbers determined with ImageJ.  
Alizarin red staining (Calcium) 
Cells were fixed for 15min with ice-cold ethanol, afterwards washed with tap water. 
5ml of a solution of 1mg/ml alizarin red in distilled water, pH 5.5 were added. The 
petri dishes were shaken for 2h, afterwards washed with tap water and allowed to 
dry. Images were analyzed for calcium amount using ImageJ. 
Sirius red staining (Collagen) 
Cells were fixed in ice-cold ethanol for 15min and washed with tap water. 1mg/ml 
sirius red was solved in picric acid. 5ml of the mixture was added to the cells and the 
petri dishes shaken for 18h at room temperature. Then the cells were washed with 
tap water till red color was completely eluted. The dishes were photographed and 
analyzed for the amount of collagen (ImageJ). 
Methylene blue staining (total colony numbers) 
Cells were fixed in ice-cold ethanol for 15min. They were washed in tap water. 
1mg/ml methylene blue was solved in 10mM borate buffer, pH 8.8. 5ml of the mixture 
was added to the petri dishes and shaken for 30min. The dishes were washed with 
tap water until all dye was eluted, photographed and analyzed using ImageJ. 
Astrocyte conditioned medium 
Astrocyte conditioned medium was produced by incubating medium (DMEM/10% 
FCS) 24h with primary astrocyte cultures produced as described by Sievers [2]. 
Differentiation towards microglia-like cells 
On day 1 (protocol 2) and day 4 (protocol 1), the non-adherent cells were flushed off 
and transferred to a new dish. Afterwards cells were differentiated for 6 days in 10ml 
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DMEM/10% FCS, 50% ACM and 20ng/ml granulocyte-monocyte colony stimulating 
factor (GM-CSF). Controls were cultured only in DMEM/10% FCS. 
Flow cytometry 
Cell were stained for F4/80 (AF488 labelled, eBioscience) (1:250), CD11b/CD45 
(AF488 and PE labelled eBioscience) (1:250 and 1:100) and CD34 (PE labelled, 
Caltag Laboratories) (1:100), CD45 R (RPE labelled, Southern Biotech) (1:100). Cells 
were trypsinized, centrifuged (300g for 5min) and fixed (4% paraformaldehyd). The 
fixed cells were washed with PBS, incubated for 2h at 4 °C with primary antibody, 
washed and analysed in a Beckmann Coulter FC 500 Flow cytometer. 
Phagocytosis 
3*105 cells were activated with 0.1µM phorbol myristic acid for 15min. Then they 
were incubated in 50µl DMEM/10% FCS together with 50µl 1:10 diluted opsonised 
beads (2.25*107 beads) (Sigma) for 48h at 37°C, 5% CO2. Cells were trypsinized and 
resuspended in DPBS (Invitrogen) and fluorescence was measured in a Beckmann 
Coulter FC 500.  
Oxidative burst 
3*105 cells were activated for 15min with 0.1µM PMA and controls without PMA. 
Activated and control cells were incubated with 50µM DHR123 for additional 15min. 
Afterwards the cells were fixed with 4% PFA and fluorescence was measured in a 
Beckmann Coulter         FC 500. Oxidative burst was defined as signal to noise ratio 
(The ratio of fluorescence of activated to control cells). 
Living brain slice cultures 
The brain from 2-3 month old C57BL/6 mice were transferred to cold Hank’s buffered 
salt solution (HBSS)/10% FCS (both Invitrogen). A VT 1000 S vibratome (Leica) was 
used to cut the brain in 350µm slices. The slices were culture on a membrane 
(Millicell CM 0.4µm, Millipore) at the liquid air interface of medium consisting of 50% 
DMEM/high glucose (HyClone Laboratories Inc.), 25% horse serum (Invitrogen), 25% 
HBSS (Invitrogen), 1µg/ml insulin (Invitrogen), 100units/ml penicillin and 100µg/ml 
streptomycin (Invitrogen). The brain slices were cultured for 9 days and the viability of 
the brain slices were assessed using DAPI/propidium iodide staining. For analysis 
the slice was scan using a confocal microscope (TCS SP2, Leica Microsystems). 
Invasion of living brain tissue 
On day 9 of brain slice culture, differentiated cells were treated with DIO (Invitrogen) 
for 20min, washed and seeded on the top of the brain slices. A plastic ring was used 
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to keep the cells from flowing off the slices. Cells and brain tissue were co-cultivated 
for additional 10 days [20]. After 10 days migration of cells into brain tissue was 
measured by scanning the slices with a confocal microscope (TCS SP2, Leica 
Microsystems) to a depth of 160µm. 
Statistical Analysis 
Data is presented as means ± SE. SigmaPlot 10.0/SigmaStat 3.5 software (SYSTAT, 
Erkrath, Germany) was used to perform statistical analysis. For comparison of 
different groups ANOVA was used. 
 
 
Results 
Cell populations during selective adhesion and differentiation 
The numbers of non-adherent cells in culture fell swiftly from day 0 to day 4 of 
selective adhesion (Fig. 1 B). From whole bone marrow, after 1 day of selective 
adhesion 3.5*106 non-adherent cells remained. After 4 days of selective adhesion 
cell yield was 1.7*106 non-adherent cells. 
The NA-BMC cultures were analysed at different days using flow cytometry (Fig. 2 
A). The prominent cell populations – of immature/nucleated red blood cells, 
lymphocytes, monocytes and granulocytes – were defined according to their forward 
and side scattering (Fig. 2 A) as done by other groups [21]. The fraction of these 
populations changed during selective adhesion (Fig. 2 B). The fraction of 
lymphocytes decreased significantly from 35.6% to 10.7% during the 4 transfers of 
non-adherent cells (P<0.05). The population of immature and nucleated red blood 
cells (NRBC) increased from 28.2% to 50.8% (P=0.13). Monocyte and granulocyte 
populations did not change during the cultivation (Fig. 2 B). The cells derived using 
protocol 2 still had a prominent lymphocyte population while the cells from protocol 1 
lacked lymphocytes (Fig. 2 A and B). The supernatant of each day was used for 
colony forming unit (CFU-f) assays. The frequency of methylene blue positive 
colonies doubled (P<0.05), alkaline phosphatase (ALP) and calcium positive colonies 
tripled (P<0.01), while collagen positive colonies did not change significantly (Fig. 2 
C). 
Marker expression levels 
As this technique was not used before for the derivation of microglia, we wanted to 
describe the cultures in some detail and the changes occurring over time. During the 
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selective adhesion period, using protocol 1, cell granularity doubled and the mean 
cell size decreased 3 fold (Fig. 3). We were especially interested in the frequency of 
cells expressing macrophages/microglia markers and hematopoietic progenitor 
markers. The median of CD34 expression tripled significantly (P<0.05), as well as 4-
fold CD45 R expression (P<0.05) and doubled F4/80 expression (P<0.05). No 
change of CD45 expression was observed. CD11b expression decreased, 
significantly, 3-fold (P<0.05) during the 4 days of selective adhesion (Fig. 3).  
Microglia differentiation 
The selection of non-adherent cells by adhesion was combined with differentiation 
media. Our new cell culture protocol (protocol 1) was compared with the classical 
approach (protocol 2).  
It is difficult to differentiate between macrophages and activated microglia. We used a 
combination of non-exclusive markers and typical morphology (ramification) as 
specific signs of microglia (resting macrophages) as suggested by [22]. In addition 
we used the combination of CD11b/CD45 expression as employed by other groups 
[22, 23] and the macrophage marker F4/80.  
The cells derived using protocol 1 and 2 were differentiated to microglia with 
astrocyte conditioned medium (ACM) and granulocyte-monocyte colony stimulating 
factor (GM-CSF) supplementation for 6 days. The cells differentiated using protocol 1 
were as efficient producing microglia-like cells as protocol 2 – judged by the marker 
combinations suggested to be specific for microglia (Fig. 4 and Fig. 5).  
Functional tests 
Microglia derived using protocol 2 showed a significantly higher phagocytosis rate 
(1/4 higher) than the cells from protocol 1 (Fig. 6 A). Supplementation of ACM and 
GM-CSF lead to a significant, 4 fold increase in the phagocytic ability of the 
differentiated cells in both protocols. It is interesting to notice that cells of both 
ACM/GM-CSF supplemented and unsupplemented cultures show almost the same 
marker expression (Fig. 4 BCD, Fig. 5 C) but differ in phagocytosis (Fig 6 A).  
Microglia from cultures of protocol 1 showed the same capacity for an oxidative burst  
as microglia derived from protocol 2 cultures (Fig. 6 B). Cytokine supplementation 
significantly increased oxidative burst in cells derived using protocol 2 - that was 
present both in supplemented and unsupplemented microglia from protocol 1. 
Morphology 
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Cells derived from protocol 1 show many small and non-adherent cells and all 
differentiated cell populations show mixed morphologies as is typical for microglia 
cultures (Fig. 6 C-F). Extensive ramification was, however, not visible.  
Organotypical brain slices 
The cells differentiated with the new protocol 1 invaded living brain tissue to a depth 
of up to 80 µm (Fig. 6 J). Most of the cytokine differentiated cells and the un-
supplemented cells migrated into the surface of the slices to a depth of 30 µm.   
Cells differentiated from classical derived macrophage showed amoeboid 
morphology (Fig. 6 I, J). Cells differentiated from NA-BMCs showed round 
morphologies (Fig. 6 G, H). In our qualitative migration experiments cells treated with 
ACM/GM-CSF or cells derived from early NA-BMCs migrated deepest (Fig. 6 J). 
 
Discussion 
Microglia derived from adult material are difficult to obtain. Most studies have been 
performed on microglia from neonatal sources and cell yields from adult sources are 
low. In  settings where cells would be used clinically, autologous sources are 
preferable. Bone marrow cells are routinely used for transplantation and contain 
different stem cell types. We have established here a protocol for the derivation of 
functional microglia using adult bone marrow providing a source for cell therapy or 
drug development. It is assumed that in the healthy brain microglia are replenished 
locally but that under pathological conditions and inflammation bone marrow derived 
cells can invade the brain and differentiate to microglia [24].  
We used a stem cell cultivation method which was originally developed to expand the 
undifferentiated stem cell population [3, 25] and tested their use as source for 
microglia. Repeated selective adhesion, as employed to derive non-adherent bone 
marrow cells (NA-BMCs), result in a rising capacity of NA-BMCs to form CFU-f. This 
as well as the high CD34 expression shows that the frequency of stem cells or 
progenitors increases during time in these cultures. The lymphocyte population in the 
new suspension cultures (protocol 1) gets diminished by the repeated adhesion and 
the fraction of immature cells increases. This corresponds to results from other 
groups showing in rats the increase of CFU-f initiating cells during the repeated re-
plating steps [3]. The results for the monocyte lineage were mixed and we can not 
conclude if during the initial culture phase the numbers of progenitors for microglia 
are diminished or not. 
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Microglia differentiation: No single marker distinguishes microglia from 
macrophages. Some publications suggest that CD45 and CD11b together might 
distinguish between microglia and macrophages [26]. CD45 is a marker for the 
hematopoietic cells and F4/80 for microglia and macrophages [27]. Our new protocol 
using non-adherent bone marrow cells showed the same level of differentiation 
towards microglial cells expressing CD11b+/CD45low and F4/80+, which, together with 
morphology (ramification), define the microglia population as described by previous 
studies [22, 23]. Functional microglia derived using the new protocol 1 showed 
slightly less phagocytosis activity than those of protocol 2, but the burst activity was 
of the same level. 
The lower phagocytosis of cells from protocol 1 might be due to less differentiated 
and more primitive cells in the supernatant of day 4. It might also be an effect of the 
longer time in culture before differentiation. That phagocytosis is low in absence of 
cytokine supplementation is known [28]. Oxidative burst of the differentiated cells is 
not significantly higher than that of whole bone marrow. Although there are 
subpopulations in whole bone marrow that do show strong oxidative burst this might 
point to an immature microglia cell type [29]. 
Morphologies were mixed and only few cells showed clearly branches typical for 
primary resting microglia as one would expect when cells were incubated with 
astrocyte conditioned medium. The amoeboid and round cell morphology in the co-
culture with brain slices indicates an active state in all tested protocols. This might be 
induced by the apoptotic cells in the slice. It is known that microglia of the brain slices 
migrate to the surface and phagocytize debris there [30].  
Conclusion: Repeated selective adhesion enriches for stem cells and provides great 
numbers of microglia, which are functionally active. This protocol provides functional 
adult microglia which can be used for drug development or cell therapies. 
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Figure legends 
 
Figure 1: (A) Overview showing the two differentiation methods. Representative 
forward scatter (FSC) and side scatter (SSC) plots of NA-BMC are shown. Day 0 – 
day 4: Phase of selective adhesion. Day 4 - day 10 and day 1 - day 7: 
Differentiation phase. (B) Yield of non-adherent cells per whole bone marrow on day 
1 – day 4. Repeated selective adhesion results in a falling number of cells. 
 
Fig. 2: (A) Scatter plots of NA-BMC during the selective adhesion phase. The 
indicated regions define populations of immature and nucleated red blood cells, 
lymphocytes, monocytes and granulocytes. P is the probability of the null hypothesis 
of the linear regression, i. e. that the percentage fraction does not change over time. 
(B) Changes in the percentage fraction of the cell populations is shown. Lymphocyte 
fraction is diminished by selective adhesion. (C) CFU-f grown from NA-BMCs of day 
1 to day 4. Methylene blue staining was used to determine total colonies. Alizarin red 
(Calcium), Sirius Red (Collagen) and alkaline phosphatase (ALP) staining were used 
to detect the capacity of NA-BMC for osteogenic differentiation. 
 
Figure 3: Median of NA-BMC antigen expression during day 0 – day 4 of selective 
adhesion. Both markers of differentiated (F4/80) and undifferentiated hematopoietic 
cells (CD34) rise. Cell size gets smaller, larger cells seem to become adherent. The 
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regression tests for a statistically significant change over time. P is the probability of 
the null hypothesis – that marker expression does not change over time. 
 
Fig. 4: (A) Representative scatter plots of differentiated cells. A microglia gate was 
set, defined by the primary microglia population, to assess differentiation. (B) Percent 
of CD11b/CD45low (microglia gate) among the differentiated cells. Yields of cells 
showing the microglia markers are not different between the two protocols. A small 
subpopulation in fresh bone marrow (20%) shows microglia markers from the 
beginning. (C) and (D) Percent of CD11b+ and CD45+ cells among the differentiated 
cells. CD45 is already high in fresh bone marrow. P1: Protocol 1. P2: Protocol 2. *** = 
P < 0.001, ** = P < 0.005, * = P < 0.01 
 
Fig. 5: (A) Representative histogram plots of F4/80 expression. Gray line is the 
isotype control. (B) Percent of F4/80+ cells among the differentiated cells. Protocol 2 
shows higher F4/80 expression than protocol 1 although, during selective adhesion, 
F4/80 rose steadily. P1: Protocol 1. P2: Protocol 2. *** = P < 0.001, ** = P < 0.005, * 
= P < 0.01 
 
Fig. 6: (A) Phagocytic activity of differentiated cells. Cells of the classical pre-plating 
protocol 2 show significantly higher phagocytosis of fluorescent beads. Cells un-
supplemented with ACM and GM-CSF show low phagocytosis. (n = 3). (B) Oxidative 
burst of the differentiated cells is not different between protocol 1 and protocol 2. P1: 
Protocol 1. P2: Protocol 2. (n = 3). 
(C-F) Differentiated cells of protocol 1 are smaller and contain many non-adherent 
cells. Morphologies and resulting cell types are diverse. Images were taken with a 
Leica DMIL at 200x magnification.  
(G-J) Most differentiated cells survive in co-culture and remain largely amoeboid and 
round, typical for activated states. The cells were co-cultured with living brain slices. 
Top down and side view pictures. Differentiated cells were labeled green (DIO) and 
transferred onto 9 day old living brain slices. Dead cells were labeled red (propidium 
iodide). After 10 days of co-culture a Leica Microsystems SP2 confocal microscope 
was used to scan the brain slices to a depth of 160 µm (Magnification 100x). (H, J) 
Cells of the cytokine supplemented cultures invade surface up to a depth of 60 µm. 
*** = P < 0.001, ** = P < 0.005, * = P < 0.01 
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Abstract 
Microglia are the resident phagocytes of the brain. They play an important role in 
several age related diseases. A loss of function of aged microglia and replicative 
senescence might contribute to diseases like Alzheimer or Multiple Sclerosis. 
However, a cell replacement therapy is difficult because cell migration in and out of 
the healthy, non-diseased brain is absent or low. This is a considerable challenge for 
the application of cells. Therefore, we provide here an overview of parameters and 
conditions that influence migration to and from the mouse brain.  
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Introduction 
Microglia: Microglia comprise about 10% of the cell population of the brain [1]. They 
perform phagocytosis, are cytotoxic, present antigens and promote repair after injury [2]. 
Under healthy conditions, microglia are quiescent. Microglia functions like phagocytosis, 
immune response and migration are down-regulated. The cells are ramified and display long 
and branched processes [3, 4]. 
Microglia are often compared to monocytes or viewed as immature macrophages 
because of their differentiation properties [5]. This definition is somewhat fluid 
because of the lack of distinct properties or markers – apart from morphology – that 
set these cell populations apart. 
Microglia in Disease: In response to inflammation, microglia become ‘activated’. Their 
morphology changes to an amoeboid shape in mice. Proliferation is up-regulated by 
inflammation [6-8]. Microglia migrate, over the course of 1-2 days, towards injury and 
extracellular debris [9]. 
The general quiescence and graded up-regulation of microglia activity might exist to 
minimize damage to neighboring neural tissue if an immune response is initiated [10]. 
If microglia are chronically activated, they have been observed to act cytotoxic and 
damage cells in the vicinity [11].  
Microglia in Age: In brains of older humans, deterioration of microglia is observable 
[12]. In the aging human brain, dystrophic microglia are present which show de-
ramification, atrophy, fragmentation and swelling [12]. In vitro cultured microglia, if 
exposed to amyloid protein, are degenerating faster [13]. This has also been reported 
by others, and an overload of the intracellular mechanisms to break down digested 
proteins (proteasome) might be responsible [14-16]. 
Microglia in Therapy: Migration to and from the healthy, young brain is absent or 
low [17]. Such cell migration is influenced by a wide range of parameters and 
conditions like injury and cell death in the brain, resulting migration signals, the 
permeabilization of the blood brain barrier due to various conditions like irradiation, 
toxins and age. There are, furthermore, indications that stem or progenitor cells in the 
bone marrow are necessary for migration into the brain [18]. In a therapy, the 
treatment of cells prior to application, application routes but also cell dose, survival, in 
vivo proliferation and many other factors play a role (Table 1).  
 
Migration during Development 
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Colonization of the Brain: The central nervous system (CNS) is populated by 
microglia progenitors on (embryonic) days 10-19 in rodents [19]. In man, this 
colonization takes place between pre-natal months 3-5. Microglia appear within CNS 
before vascularization [20] and before monocytes are produced in hemopoietic 
tissues [5, 20]. This seems to occur partially in response to cell death and related 
signals [20]. 
The natural routes on which microglia precursors might migrate into and colonize the 
brain are the ventricular layer, the pial surface of the meninges, and here especially 
the areas of the optical tectum and cerebellum, and the endothelial wall of the later 
established vasculature (Fig. 1) [19, 20]. Cells adhere to the endothelial walls of the 
bloodvessels and ‘squeeze through’ the endothel much like macrophages and 
monocytes do in other tissues (Ibid.). For microglia precursors there is evidence that 
adhesion is mediated by LFA-1/ICAM-1 (lymphocyte function-associated antigen-
1/intercellular adhesion molecule-1) [21]. At the time microglia precursors invade the 
developing brain, ICAM-1 expression in the endothel and LFA-1 positive cells are 
present in the vessel. Furthermore, microglia seem to cross the ventricular layer 
during early development [22]. Similar observations exist for prominent points of the 
pial border and microglia in the optic tectum and cerebellum might derive from such 
sources [20]. 
In the adult organism, in principle, the same routes of migration to and from the brain 
would be possible – however, the endothelial wall becomes much less permeable in 
the mature brain (blood-brain-barrier). 
 
Migration under Healthy Conditions 
Migration in the Brain: Under healthy conditions, microglia are ramified. It has long 
been thought that in this state microglia are virtually non-motile. However, in vivo 
motion picture observations have shown that microglia are in fact continuously 
forming protrusions that are extending and withdrawing [3]. This is similar to 
extensions in macrophages, which act to draw debris to the cell body for 
phagocytosis. The long and branched processes of ramified microglia might monitor 
the local neighborhood in this way. 
Microglia are activated through distinct pathways and can respond both anti- and 
proinflammatory [15]. If microglia encounter cell debris, receptors recognizing 
phosphatidylserine in apoptotic membranes drive their response (Ibid.). Other groups 
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emphasize the importance of oxidized proteins and lipids in apoptotic cells and their 
recognition by vitronectin receptors, scavenger receptor B1 (CD36) and CD14 [23]. 
Many receptors seem to be involved in these mechanisms and seem to be highly 
redundant (Ibid.). They might also help in ‘tethering’ the apoptotic cell while only 
certain receptors signal via associated proteins [24]. 
The loss of function of certain receptors like the triggering receptor (TREM2) or 
DNAX-activating protein 12kDa (DAP12) has been observed to lead to an 
inflammatory neurodegenerative disease later in life [25]. Tim4 (T-cell 
immunoglobulin- and mucin-domain-containing molecule-4) recognizes 
phosphatidylserine [26]. Purine receptors active in phagocytosis of microglia like 
P2Y6 recognize UDP from injured neurons [27]. 
The removal of such ‘normal’ debris takes place without full activation or strong 
movement of the cell body. Here, microglia perform a ‘silent’ phagocytosis [15] and 
act anti-inflammatory. They show anti-inflammatory cytokines like tumor growth factor 
beta (TGF-beta) and interleukin 10 (IL-10) [24]. 
The pro-inflammatory pathway is discussed in the chapter covering diseased 
conditions. 
The Blood Brain Barrier: One of the routes to enter the brain is migration through 
the bloodstream. Because of the differing specialization of organs, blood vessels are 
adapted to that function. For example organs, which have filtering function (liver), or 
provide red blood cells (bone marrow), display porous or even open vessels. The 
CNS however is shielded from the bloodstream by a tight endothelial barrier, the so 
called blood brain barrier (BBB) [28, 29]. Some parts of the brain, the 
circumventricular organs, are not covered by the blood brain barrier [30]. Examples 
are the pituitary gland, that secretes hormones like oxytoxin or vasopressin 
endocrinal, or the area postrema . 
This barrier serves as a protection from drugs and harmful substances, infections and 
overreaction of the immune system. It only becomes more permeable under 
pathological conditions. Therefore, it has been discussed controversially whether, 
later in life, a migration of cells through this barrier takes place. 
Migration across the BBB: In unlesioned hemipheres of the brain, migration of 
bone marrow cells is restricted to sites of macrophage turnover like meninges and 
the Virchow-Robin spaces (Fig. 2) [31]. Without irradiation, cell migration to the brain 
is absent or low [18]. Massberg et al. observed that parabiotic, hematopoietic stem 
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and progenitor cells (HSPC) in the peripheral blood of beta-actin/GFP mice [32] did 
not migrate into the brain of C57BL/6 partners over the course of 14 days [33]. 
In view of bone marrow transplantation experiments, other groups had hypothesized 
that the microglia cell population might be replenished at a slow rate by bone marrow 
derived progenitors, which migrate over the circulation to the brain [10] and that, in 
this way, a slow turnover of microglia might take place [2]. 
Dynamics of the healthy Circulation: Migration of cells between organs is often 
approached by the idea of migration equilibrium [33-35]. This circulation, in the 
healthy state, of course occurs mainly between more ‘open’ organs than the brain. In 
the healthy mouse brain migration is severely restricted by the tight endothelial wall 
encasing the brain, the blood brain barrier. That dramatically changes if cell death in 
the brain occurs (See chapter on diseased state). A plethora of observations allow to 
roughly determine the dynamics of stem and progenitor generation and migration in 
the healthy circulation. 
Parabiotic blood HSPC reached a 40% chimerism in the peripheral blood of the 
partner and high chimerism in ‘open’ organs like spleen, lung, lymph, liver and kidney 
[33]. However, only 5% chimerism in bone marrow and almost none in the brain 
could be detected. 
According to van Furth et al. [34], monocytes leave the circulation randomly with T1/2 
= 17.4h. The number of monocytes present in the circulation of a healthy, adult 
mouse is  about 4,4*105 or 6.18*105 [34, 36]. In the healthy state about 5*105 
promonocytes in total mouse bone marrow generate ca. 0.62*105 cells/h [34].  
In the experiment by Massberg et al. parabiotic HSPC showed about 36h retention 
time in peripheral tissues before they remigrated to the blood. This was determined 
by disconnecting the parabiotic partners after 14 days and measuring the time course 
of the drop of chimerism [33]. 
Such observations give insight into cell turnover in the circulation and tissues, how 
migration and proliferation behavior changes in disease, injury or age and how 
transplanted cells will behave. They can be applied to design therapies. 
Intrinsic Proliferation: In the healthy, young brain microglia are capable to 
proliferate locally and do not necessarily require replenishment from circulating 
progenitors [18, 37]. Also, microglia cell numbers in the brain are regulated by 
apoptosis [31, 38, 39]. 
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Migration under Diseased Conditions 
Migration in the diseased Brain: If microglia are completely activated, they 
withdraw processes and the whole cell body moves to the site of injury or plaques [9]. 
This holds also true for cells other than resident microglia. If a hemisphere of the 
brain is injured by intracerebral injection of LPS, intracerebral MSC migrate to the site 
of injury and proliferate locally [40]. 
The removal of ‘normal’ debris takes place without full activation or strong movement 
of the cell body (See section on healthy conditions). The role of microglia seems to 
be dependent on distinct sets of surface receptors involved in phagocytosis [15]. 
Receptors recognizing microbes, for example toll like receptors (TLR), stimulate a 
pro-inflammatory response. Microglia activated in this way excrete signals associated 
with inflammation, like tumor necrosis factor (TNF), interleukin IL-1 and nitric oxide 
(NO). 
When microglia were co-cultured with brain tissue and treated with 
lipopolysaccharides (LPS) they acted neurotoxic. Contrarily, if they were activated 
with interleukin 4 (IL-4), the microglia acted neuroprotective in co-culture [15, 41]. IL-
4 regulatory macrophages can support organ transplantation [42]. 
Migration across the BBB: In lesioned brain hemispheres (enthorinal cortex lesion) 
[31], migration of bone marrow cells to the hippocampus was observed, across the 
BBB, contrary to the unlesioned state (Fig. 2). 
Bone marrow derived microglia can be observed in the brain after systemic 
transplantation [43]. However, while bone marrow (BM) chimeras have shown BM 
derived microglia [44], experiments indicate that parabiotic circulating blood is not 
sufficient and bone marrow is necessary for invasion [18]. 
Other groups could observe migration of intravenously injected hematopoietic stem 
cells to the brain in ischemic mice. They differentiated to microglia and reduced 
infarct size [45]. 
Migration Signals: The invasion of microglia into the central nervous system during 
development occurs coincidentally with neuronal cell death [20]. Cell death, disease 
and injury induce various migration signals. Among others monocyte chemoattractant 
protein 1 (MCP-1), interferon gamma inducible protein (IP)-10, macrophage 
inflammatory protein (MIP)-1alpha, MIP-1beta and MIP-2 [46]. These chemokines 
seem to be produced mainly by resident microglia and astrocytes and provide signals 
for homing of leukocytes to the site of injury and across the BBB (Ibid.). 
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 It is, therefore, apparent that cell death or a disruption of the BBB might result in 
migration of cells into the brain. However, it is difficult to elucidate the contribution of 
chemokines and a possible breakdown of the blood brain barrier to cell migration. 
Facial nerve axotomy (FNA) – a lesion that does not perturb the blood brain barrier – 
does not suffice for migration of bone marrow cells into the brain [17]. The group 
observed that irradiation is necessary for invasion. 
Irradiation leads to endothelial cell death (Apoptosis), changes in gene expression, 
cell-cell interactions and alteration of the microenvironment [47]. The achieved 
disruption of the BBB is, for low doses, only transient (Ibid.). 
Other groups noted that irradiation is not necessary for invasion. In chimeric mice 
with green fluorescent protein (GFP) marked bone marrow cells, migration of 
monocytes from the bone marrow to the brain took place in cases of injury like facial 
nerve axotomy, fimbria-fornix transsection, cuprizone demyelination and stroke [31]. 
All of these findings indicate that cells in peripheral blood do not migrate to the brain 
and that mobilization of bone marrow cells are necessary. Also, that irradiation, 
certain types of injury (facial nerve axotomy, fimbria-fornix transsection, cuprizone 
demyelination and stroke) and the associated migration signals are necessary 
conditions for migration of such cells to the brain. 
Dynamics of the diseased Circulation: Already hypoxia and stress suffice to 
mobilize cells into the circulation (Zhang, 2009). Also cytokines like GM-CSF can 
mobilize HSC into the bloodstream [32] Mimicking mild inflammation of the lungs or 
peritoneal cavity with LPS or infection, both intranasally and intraperitonally, a 
decrease of circulating monocytes was observed by Burke et al. [36]. This decrease 
was interpreted as recruitment of circulating monocytes to the infected site. 
Under more serious or acute conditions, for example stroke, the circulating monocyte 
count increases, however lymphopenia is observable [48]. In such acute cases 
increased systemic proliferation and, in the case of stroke, immunodepression [49] 
form a more complex interplay than in mild inflammation.  
Intrinsic Proliferation: If an injury is caused through facial nerve axotomy, initially 
local neuroinflammation and enhanced proliferation of microglia take place. The 
regeneration of axons is completed over a time frame of about 4 weeks. At this time, 
the microglia activity has already ceased [10]. 
Migration from the Brain: After brain invasion by circulating monocytes in the case 
of a lesion [31], numbers of microglia/macrophages decrease to normal levels 
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possibly by apoptosis and migration out of the brain [38, 39]. It has been proposed 
that this might involve presentation of antigens in lymph nodes [50]. GFP monocytes 
migrated from the intracerebral lesion site to deep cervical lymph nodes in 7 days 
[51]. Such behavior corresponds to the normal migratory circulation of HSPC in more 
‚open’ organs [33]. 
 
Migration in Age 
Migration in the Brain: The functions of microglia like phagocytosis, oxidative burst 
and cytokine production are impaired in age [10, 14-16, 52-54]. This seems to be 
partially due to a deterioration of the cells themselves, but also caused by the aged 
environment. In transplantation experiments, old donor leukocytes performed worse 
than young did and young leukocytes performed worse in old hosts [55]. 
Migration across the BBB: It is a well studied fact that vessels become more 
permeable in age (Fig. 2) [56, 57]. Furthermore, there is evidence that the 
regeneration of aged vessels by proliferation and endothelial progenitor cells is 
impaired [58]. BBB permeability increases with normal aging [56, 57]. This might lead 
to diffusion of harmful substances from the blood into organs and to a constant 
inflammation throughout the body in old age [56, 57]. It might also contribute to the 
incidence of neurodegenerative diseases, caused by a chronic activation of immune 
cells. Other potential reasons of this observed „Inflamm-Aging“ are antigens and 
stress [59]. 
Such a porous blood brain barrier, but also an inflamed brain, might change the 
migration behavior of cells across the BBB in age. Dauer et al. compared migration in 
8 week (young) and 52 week (advanced middle age) mice in case of facial nerve 
axotomy and observed differences in the invasion of T cells into the brain [60]. This 
was mainly attributed to possible differences in the inflammatory response in aged 
animals. Hurley et al. observed similar differences and mentioned that BBB 
breakdown in age might be underappreciated [61]. 
Intrinsic Proliferation: Some groups hypothesized that resident microglia reach 
replicative senescence in old age [10]. This has been linked to the development of 
neurodegenerative diseases, especially Alzheimer, in humans but not in rodents. It is 
simply suspected that, in case of short life spans, a replicative senescence and 
complementary deterioration of the microglia cell population does not take place [10]. 
In old rats there have been indications that proliferation of microglia after injury is 
5.  PAPER 3: “To Migrate or not to Migrate – Microglia and Cell Migration to and from the Brain” 68 
stronger than in young rats [62]. In vitro, microglia have been reported to undergo 
telomere shortening [12]. In vivo, however, there are reports of higher telomerase 
activity and stable telomere length of FACS sorted microglial cells after their 
proliferation was induced by facial nerve axotomy [63]. 
 
Migration in Therapy 
Application of Cells: In principle, cells can be delivered via the same routes as 
microglia progenitors migrate into the brain during development. MSC have been 
delivered intranasally and migrated into the brain [64]. Intravenous injection of GFP-
transgenic bone marrow cells after whole body irradiation resulted in reconstitution of 
the bone marrow and colonization of the brain [43]. Cells can also be directly injected 
intracerebrally [40]. 
Cell Size: During the injection procedure, small bore diameter and pressure of 
syringes have detrimental effects on cell viability [70]. Larger bore diameter reduces 
these effects. Cells that remained for a longer time in syringes showed reduced 
viability while cells at room temperature fared better. Cells stored at 4°C performed 
worse than cells in the syringe (Ibid.).  
In the case of intravenous injection, but also on other application routes, cell size 
strongly influences migration behavior. Especially larger cells, like mesenchymal 
stem cells (MSC), are often stuck in the lungs for a certain time, resulting in 
respiratory problems and even death [71]. In fact, minutes after intravenous injection, 
MSC are mostly situated in the lungs. Then they relocate to other organs, for 
example to liver and bone marrow [72]. Therefore, on the way to the target organ, a 
large amount of cells is stuck, filtered out of the blood stream or simply entering other 
tissues. Cells injected intravenously do not all – as is often nearly insinuated – home 
directly to a certain organ and treat a certain disease. Instead, such an application is 
obviously an undirected treatment of the whole organism involving migration of cells 
to a variety of organs, engraftment and other effects. This occurs especially in the 
absence of migration signals caused by lesions, infections or degeneration. 
Cell Type: Ajami et al. observed that parabiotic blood cells do not suffice, even if the 
parabiotic partner was irradiated, to observe migration to the brain and that bone 
marrow is necessary [18, 65]. In this way the group showed that certain bone marrow 
resident stem or progenitor cells might have the ability to migrate into the brain. At 
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the same time, differentiated cells might be unsuited for migration into the brain (Fig. 
3). 
Various cell types display the ability to ‘home’ to certain associated organs or sites of 
injury. The transplanted cell type can, therefore, have an impact on the successful 
migration into the brain. The developmental migration of microglia fueled the 
hypothesis of a directed homing of microglia progenitors to the brain [66]. In the case 
of intravenous injection, epidermal neural crest stem cells and bone marrow derived 
MSC, when LPS, injected intracerebrally, induced demyelination, migrated to the site 
of injury (8% of injected cells) [40]. HSPC did not migrate to the brain [33]. 
Lymphocytes are known to migrate to lymph nodes and spleen [67]. 
Treatment of Cells: Before transplantation, cells are often treated in various ways. 
Cell culture, simple exposure to oxygen or enzymatic treatment can have drastic 
effects on migration properties, homing, cell survival and differentiation. 
Homing properties of bone marrow cells are destroyed by prolonged in vitro 
expansion [68]. It is known that fresh bone marrow is generally better suited for 
reconstitution of the immune system than bone marrow cells which have been in 
culture over longer periods. Stem and progenitor cells differentiate because of 
exposure to oxygen, adherence or culture density [69]. However, such in vitro 
cultivated BM cells are not only less suited for reconstitution but also have a highly 
reduced ability to reach spleen or bone marrow [68]. In a similar way, possible 
special migration properties of microglia progenitors might be compromised [66]. 
Trypsinization destroys surface adhesion molecules and therefore will restrict cell 
adherence and directed migration [67]. After treatment of lymphocytes with trypsin for 
5 minutes, they had lost their ability to enter lymph nodes but could still enter the 
spleen (90 min after injection). When analyzed 16 h after injection, lymphocytes could 
again be found in lymph nodes and spleen. This suggested a regrowth of the 
necessary adhesion molecules over a longer time period [67]. 
Dynamics of Transplanted Cells in the Circulation: Over a course of 2-7 days in a 
healthy mouse, injected MSC enter various tissues like liver or bone marrow [72]. 
This corresponds to theoretical considerations. Under normal conditions, monocytes 
leave the circulation randomly with a half time of 17.4h [34].  For example, 106 
monocytes would, together with the circulating and marginating cell pool of 1.5*106 
[34], result in a transient doubling of circulating monocytes. From these models, after 
1 day  a 25% chimerism remains in the circulation. After 1 week less than 0.1%. 
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Migration Signals and Permeabilization of Blood Brain Barrier: The comparison 
of cell migration under healthy and diseased conditions shows that the induction of 
certain injuries or irradiation is necessary to induce migration to the brain. Facial 
nerve axotomy does not suffice to induce migration of bone marrow cells and 
irradiation of the brain is necessary [18]. Fimbria fornix transsection, cuprizone 
demyelination and stroke result in migration of monocytes from bone marrow into the 
brain [31]. Intracerebral LPS draws epidermal neural crest cells and bone marrow 
derived MSC into the brain [40]. 
Acute injuries like stroke or even irradiation do not just result in neuronal death and 
chemokines but also disrupt the blood brain barrier. Such an indiscriminate disruption 
is dangerous as it not only damages the brain but also allows the diffusion of harmful 
substances into the brain. 
Cell Survival, Dose and Rejection: Balb/c SR/CR leukocytes convey resistance to 
cancer. When female Balb/c SR/CR donor leukocytes were injected intraperitonally 
into male Balb/c hosts, their survival was not affected by sex mismatch [55]. Survival 
of the cells was tested rather robustly by challenging the hosts with S180 cancer 
cells, 1 day to 12 weeks after transplantation, and measuring the rate of survival of 
the hosts. Male Balb/c SR/CR donors into female hosts showed only 83% survival. 
MHC mismatch resulted in 58% survival and added with female mismatch (43%). Old 
donor leukocytes resulted in lower survival of host mice than young did and young 
leukocytes archived lower survival in old hosts [55]. 
Stewart et al. hypothesized a ‘competitive engraftment’ [35]. In non-irradiated 
conditions injected and resident bone marrow cells compete for stem cell niches in 
the bone marrow. The group reported that, without irradiation, large cell doses (40-
200*106) of male Balb/c, BDF1, CBA-J mice into matched female hosts could result in 
high and stable (1 year) chimerisms of 30%-70%. With BMT, already doses of 5*106 
cells achieve a similar 40%-60% chimerism [28]. In line with this, Massbergs 
parabiosis experiment resulted in a comparatively small 5% chimerism of HSPC in 
the non-irradiated, matched partner bone marrow [33]. 
In vivo Proliferation: In vivo, proliferation induced by inflammation or irradiation can 
drastically influence the outcome of a therapy. Mildner et al. irradiated the mouse 
body excluding the brain, thereby inducing inflammation. However, cells could not be 
observed to enter the non-irradiated brain, rendering the contribution of in vivo 
proliferation to migration into the brain questionable [17]. 
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Figure Legends 
 
Figure 1: Natural migration routes in and out of the brain during development and 
possible application routes in a cell therapy. MP: Microglia progenitors, HSPC: 
Hematopoietic stem and progenitor cells. 
  
Figure 2: (A) Migration under healthy conditions. The brain is shielded by a tight 
endothelial barrier and migration in and out of the brain is low. (B) Diseased or 
injured conditions change migration behavior. Certain injuries prompt bone marrow 
(BM) cells to migrate into the brain. Acute injury also up-regulates proliferation and 
might result in immunodepression. (C) In old age the endothelial wall becomes 
porous and a general inflammation of organs results. 
 
Figure 3: Important therapeutic parameters that influence the migration of injected 
cells. In absence of migration signals due to disease or injury cell migration into the 
brain is low. Also, cell migration inside the brain is limited. 
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Table 1: 
 
Sources that investigate important Migration Parameters. 
 
Migration Parameter  Investigated in 
Cell Type Imai 1997 
Ajami 2007 
Massberg 2007 
Treatment of cells (Trypsinization, 
cultivation) 
Nolte 2001 
Szilvassy 1999 
Application 
 
Danielyan 2009 
Rodriguez 2007 
Jackson 2010 
Agashi 2009 
Cell survival, dose, rejection 
 
Stehle 2009 
Steward 1993 
Bechmann 2005 
Coyne 2006 
Cell size Gao 2001 
Schrepfer 2007 
Permeabilisation of the blood brain barrier Gaber 2004 
Mildner 2007 
In vivo proliferation Mildner 2007 
Dynamics of transplanted cells in 
circulation 
Van Furth 1986 
Massberg 2007 
Age Farrall 2009 
Valle 2009 
Migration out of the brain 
 
Kaminski 2012 
De vos 2002 
Finsen 1999 
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Abstract 
The brain changes with age and many diseases of the brain are in fact age related. 
Especially the function of the immune system and here of microglia has been linked 
to diseases developing in old age. 
To elucidate the causes and develop therapies the establishment of robust and 
dependable methods to measure such age related changes are important. Here we 
suggested the application of stereological methods to measure changes in microglia 
activity with age, so called inflamm-aging. 
We describe advantages and limiting problems of the method that will be useful to 
anyone applying stereology to biological samples. 
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Introduction 
Age related diseases of the brain have been linked to the deterioration of microglia in 
age. Among other changes, deterioration of cells [1], a loss of function [2-5] and 
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chronic activation [6] have been observed. We wanted to investigate here changes in 
activity of microglia with age. This has been done previously using non-stereological 
methods [7]. Measuring microglia ‘activity’ using immunohistochemical and 
stereological methods presents several problems, most prominently the definition of 
microglia activation but also variations in the investigated regions, time consumption, 
problems involving the staining of cells and statistical considerations. 
 
Materials and Methods 
 
Animals 
C57BL/6 mice from the animal facility (MEZ) of the University of Leipzig and Charles 
River (Sulzfeld, Germany) were used to create brain slices in accordance with local 
animal ethics regulations. Two groups were defined, a young (2-3 months) and an old 
(12 months) group. 
 
Brain isolation and cryoslices 
The mice were perfused with 4% paraformaldehyde (PFA) and the brain isolated. 
The brain was placed into 4% PFA for 1 day. Afterwards the brain was moved to 30% 
sucrose/0.1% NaN3 for 1-2 days. The brains were snap frozen in methylbutan. They 
were stored in a –80°C freezer together with some ice.  
The brains were moved from the –80°C freezer to –20°C 24h before they were cut in 
a cryostat. The part covering the hippocampus was cut in a cryostat CM3050S 
(Leica) in 40 µm slices. The slices were, using a fine brush, placed in a 48 well plate 
filled with cryo protection solution (CPS). The CPS consisted of 250 ml glycerin, 250 
ml ethylenglycol and 500 ml DPBS. 
 
Immunohistology 
The brain slices were stained over night (4°C) with mouse x MHCII (mouse, rat), 
1:500 dilution (Abcam, ab23990) and rabbit x Iba-1, 1:500 dilution (Wako, 019-
19741). They were stained for 2h in the dark with the secondary antibodies goat x 
mouse PE, diluted 1:1000 (Abcam, ab7002) and donkey x rabbit Cy2 1:1000 
(Jackson Immunology, 711-225-152). Afterwards, the slices were stained with a 
1:30000 solution of DAPI (Sigma Aldrich, D9564-10MG) and incubated in the dark for 
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20 min. The slices were placed in a box with CPS and washed onto glass slides with 
a fine brush, dried over night, mounted with DPX and dried for additional 24 h. 
 
Preliminary considerations 
The stereology system used was the Stereoinvestigator (MBF Bioscience). For 
stereology based studies statistical considerations play an important role to reduce 
the resulting error. The coefficient of error (CE) gives an estimate how large the 
contribution of the stereological estimation to the resulting statistical error is. To 
obtain a low overall error the CE should be dominated by the statistical error among 
animals. We stained every 8th slice, covering the hippocampus [8]. Lower intervals 
lower the estimation error, however do also consume more time for slice preparation 
and counting. The interval is sufficient in our case (n=3) to ensure that the error of 
stereological estimation is dominated by the variation between animals. If more 
animals are measured additional slices can be added (For example every 4th, 
including the previously counted). 
Frame and grid size (80µm x 80µm, 250µm x 250 µm) were chosen such that about 
600 - 800 cells per brain were counted. Like the interval between counted slices, 
larger numbers of counted objects lower the error of estimation and should always be 
chosen such that the resulting error of the estimation is dominated by the variation 
between animals.   
 
Results and Discussion 
 
Counting region definition 
Because biological samples are very variable one of the major error sources lies in 
the difficulty to objectively define a region in which to count cells (or other objects). 
This is especially problematic because of the easy shrinking/shearing of brain slices 
or other biological samples. 
Simply applying a box of a certain size to a random part of the 3-dimensional 
hippocampus – as often done - will clearly result in errors because both varying 
regions are measured but also the box would span regions that were originally of 
larger or smaller size. Such errors would partly be systematic, i. e. be observed as 
significant differences that do not truly exist. However, such problems can partially be 
ameliorated by calculating densities instead of using absolute numbers or volumes. 
6. ADDITIONAL DATA: Transplantation and Stereological Measurements 84 
The definition of a region in a biological sample should in the best case scale with 
shrinking/expanding or shearing. Furthermore, the region should be defined 3-
dimensional. 
We have used here the easily identifiable outlines of Dentate Gyrus and Cornu 
Ammonis to define a 3-dimensional volume in which to count (See Figure 1A). This 
definition accounts for shrinking or shearing. We count these regions in both 
hemispheres to avoid problems from accidentally mixing up the right and left 
hemisphere. Furthermore, in this region microglia are under non-pathological 
conditions evenly distributed. Such even distribution simplifies the counting in 
biological samples. Cells which are strongly accumulating in single places are often 
impossible to count. 
However this definition has also several drawbacks. In figure 1A it is possible to see 
that the ‘rear’ end of the region is open and the Cornu Ammonis becomes diffuse 
there. This might result in variation of the volume of the region. The volumes we 
determined, however, did change only very slightly between animals (Fig. 3C). 
Therefore, the inner hippocampus region marked by the Cornu Ammonis and 
Dentate Gyrus turned out to be well suited for an objectively defined region. 
Furthermore, the dense cell accumulations in the Cornu Ammonis/Dentate Gyrus 
interfere with immunohistology (see section on immunohistology). We used DAPI 
(1:10000-1:30000) to identify the structures of Dentate Gyrus and Cornu Ammonis.   
 
Immunohistology 
Depending on whether ‘microglia’ are defined as cells expressing Iba-1, other 
markers, expressing them strongly or expressing them at all, or by different methods, 
this might result in under or over estimation of microglia numbers. 
As marker for microglia we used Iba-1. It stained both processes and microglia well 
(Fig. 1B). Alternative markers would be CD11b, F4/80 and lectin. 
A problem arising in the stereological counting of microglia is the relatively 
continuous expression levels of Iba-1 in different microglia which results in a rather 
subjective cut off at which low Iba-1 staining is judged as not any more indicative of 
microglia. This subjective threshold will change between different persons counting 
cells and result in systematic errors. 
As marker for ‘activity’ of microglia we used MHC class II (Fig 2A, B, C, D) as done 
by Sheffield et al. [7]. MHC class-II is involved in phagocytosis and marks cells which 
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are highly phagocytic [9]. Microglia expressing MHC class-II have been observed to 
be hightly phagocytic while MHC-II negative microglia are not. 
Therefore, we define here ‘active’ microglia as MHC-II expressing, phagocytic 
microglia. One might argue that microglia activation from their ramified, resting state 
is not necessarily identical with increased phagocytosis – although many studies 
reported increased phagocytosis in activated microglia populations. 
There are microglia that strongly express or do not express at all MHC-II (Fig. 2A, B, 
C, D). However, most ‘active’ cells are intermediate stages of these extremes and 
express MHC-II only on certain spots. MHC-II is often expressed on the processes of 
microglia (Fig 1D) and not only on their cell body. Most of the time it is not possible to 
clearly distinguish which protusion corresponds to which microglia, especially 
because these protusions form a three dimensional network. Therefore we defined 
here ‘active’ microglia as those which express MHC-II on their cell body, not on their 
protusions. This definition is clearly motivated by the method and not at all 
biologically. It might result in systematically counting lower numbers than actually 
active microglia (Since all those which do only express MHC-II on their protusions are 
counted as ‘resting’). Furthermore, there might be biological reasons why some 
microglia express MHC-II on their protusions and others on their immediate cell body. 
MHC-II on the cell body is sometimes expressed on the whole body (Fig 2A, B) but in 
most cases only on a part (Fig. 2C, D). Often, MHC-II is observable at the spot where 
a protusion connects to the cell body (Fig. 2G, H, I, J) 
Also, other markers have been used in the past to differentiate between ‘active’ and 
resting microglia without observing cell morphology (ramification). Most of them, 
however, have been reported to be gradually up-regulated (CD45, CD68) which 
makes a clear distinction between ‘active’ and resting difficult. 
Furthermore, the high cell density in the Dentate Gyrus and Cornu Ammonis regions 
often resulted in strong MHC-II staining in these regions. In these parts of the 
hippocampus it is difficult to determine whether the MHC-II is really expressed by the 
Iba-1 positive microglia in question or lying on top or below the cell. 
 
Microglia numbers and activity 
We could observe significant differences in microglia activity between young (2-3 
months) and adult (12 months) mice (Fig. 3D). Sheffield et al. showed a significant 
increase of MHC-II in normal brain aging of rodents and primates [7] Also microglia 
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numbers are significantly different – however, when the density is calculated this 
vanishes (Fig. 3A, B). There have been reports of rising microglia numbers in female 
mice [10]. However, here variations in the volume of the counting regions are 
responsible for this. 
 
Coefficient of error 
When on every 8th slice hippocampi of both hemispheres were counted, the 
coefficient of error of the stereological estimation (CE) was always at or below 0.05. 
Compared to the resulting statistical errors between samples, this error of estimation 
did not dominate the errors by animal variation or immunohistology. For example, the 
absolute microglia numbers determined for young animals were 67490. The resulting 
standard error was 6106. On the other hand, the CE value in these 3 cases was 
0.05, 0.05 and 0.04. The resulting error of the estimation was therefore 3375. As is 
desired, the CE value was dominated by variations between animals. 
For calculation of the CE (coefficient of error) we used here the error estimation of 
Gunderson with the assumption of m=1 [11] – assuming that the counted volume and 
the counted microglia are smooth and evenly distributed. Use of m=0 results in a 
slightly higher CE (<0.06) that is, however, still dominated by the statistical error. If 
more animals are counted, the intervals of counted slices and grid size would have to 
be lower for best statistical results. 
 
Outlook 
Since robust measurements of age related changes are important for their 
investigation and for the development of therapies, the reproduction of the here 
reported significant differences in microglia activity by other groups would be 
important. Also, since the age difference is low (young and adult mice), an extension 
to older mice and also other species would be interesting. 
MHC-II, used here as activity marker has certain advantages and drawbacks over 
other markers. It would be advantageous to compare different markers that are 
clearly expressed on active, but not on resting, microglia and to find markers which 
are exclusively expressed on the cell body and better suited for the highly dense 
Dentate Gyrus/Cornu Ammonis. 
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Figure legends 
 
Fig. 1: (A) The hippocampus region was defined by the outlines of the Cornu 
Ammonis and Dentate Gyrus. (B, C) Representative pictures of microglia in brain 
slices stained with Iba-1 (Green). (E) Overlay of (C) with red (MHC class II) channel 
(D). MHC class II is co-localized with microglia processes and the microglia cell body. 
 
Fig. 2: (A, B) Example picture of a microglia cell body completely covered with MHC 
class II (‘active’) (MHC class II red, Iba-1 green). (C, D) Example picture of a 
microglia cell body completely devoid of MHC class II (‘inactive’). (E-J) Examples of 
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intermediates (‘active’). MHC class II is often expressed at the link between 
processes and cell body. 
 
Fig. 3: (A-D) Stereological estimation of absolute numbers of microglia in 
hippocampus, hippocampus volume, microglia density and activity in young mice 
(‘Young’, 2-3 months) and adult mice (‘Adult’, 12 months) (n = 3). Error bars shown 
are standard error (SE) of the mean. Statistical analysis by ANOVA: *** = P < 0.001, 
** = P < 0.005, * = P < 0.01 
 
Fig. 4: (A-D) Effect of MSC transplanatation. There is a non-significant probability 
(0.08) that MSC transplantation influences microglia activation. (‘Young’, 2-3 month 
mice) (‘Adult’, 12 month mice) (n = 3). Error bars shown are standard error (SE) of 
the mean. Statistical analysis by ANOVA: *** = P < 0.001, ** = P < 0.005, * = P < 0.01 
 
Fig. 5: (A-D) NA-BMC transplantation does not influence microglia numbers and 
activity in the hippocampus. (‘Young’, 2-3 month mice) (‘Adult’, 12 month mice) (n = 
3). Error bars shown are standard error (SE) of the mean. Statistical analysis by 
ANOVA: *** = P < 0.001, ** = P < 0.005, * = P < 0.01 
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7. Discussion 
 
Aims 
 
Alzheimer or Multiple Sclerosis might be connected to a chronic activation or loss of 
function of microglia in age [1]. Functional microglia differentiated from adult stem 
cells might be transplanted to resolve these problems.  
 
We aimed to: 
 
1. Differentiate microglia from adult stem cells (mouse bone marrow) and proof 
their function (Paper 1 and 2) 
2. Observe migration, survival and microglia morphology in co-culture with brain 
tissue (Paper 1 and 2) 
3. Transplant microglia and MSC, track cells and stereological measurement of 
microglia numbers and activity (Paper 3 and additional data) 
 
Differentiation of Microglia 
 
Microglia differentiation: We screened several protocols for differentiation of 
functional microglia from bone marrow (Data not shown). A number of these 
protocols resulted in cells showing markers, morphology and function of primary 
microglia (Paper 1 and 2). 
To date, several protocols to differentiate microglia have been reported. Peripheral 
blood monocytes, bone marrow, bone marrow subpopulations and ESC have been 
differentiated to microglia [4-7]. 
It was interesting to note that in all of these protocols populations of non-adherent 
cells are employed which are then differentiated either in ACM or with cytokines. The 
various reported protocols differ mainly in the in vitro culture time before non-
adherent cells are selected. Also, they differ in differentiation times and in culture 
densities and media composition. Especially the differences in media and culture 
densities make it hard to directly compare the protocols of different groups to each 
other.  
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We used GM-CSF and ACM as opposed to ACM alone [6] or M-CSF used by 
Davoust et al. [5]. GM-CSF has been reported to expand primary microglia more 
successfully than M-CSF [9, 71].  
The differentiation to microglia has, to date, been judged using non-exclusive 
markers and morphology by other groups [6]. Primary microglia have been 
characterized as CD11b+/CD45low and have been discerned from primary 
macrophages by their morphology and CD45 expression level [66, 67]. 
Markers: Our BM derived microglia showed similar expression levels of CD11b, 
CD45 and F4/80 as primary microglia (Paper 1 and 2). However, also a bone 
marrow subpopulation shows similar marker expression. It is, therefore, difficult to 
assess microglia differentiation by markers alone. 
Morphology: Microglia differentiated in presence of ACM/GMCSF but without Flt3L 
displayed a strong ramification as is typical for microglia [6, 30, 31]. The majority of 
these cells were ramified, pointing towards a high purity of the non-adherent cells of 
day 11 bone marrow culture. Servet-Delprat et al. observed 20% of differentiated 
cells to be ramified  [6]. 
Function: Bone marrow cells cultured in the presence of ACM, GM-CSF showed 
microglia-typical phagocytosis and oxidative burst activity. ACM contains M-CSF and 
GM-CSF and has repeatedly been used to induce differentiation (ramification) of 
monocytes and macrophages to microglia. 
Flt3L: Flt3L supplementation diminished the functional markers and microglia like 
morphology. Therefore, among the parameters tested here, the ‘optimal’ protocol for 
in vitro differentiation of microglia relies on ACM, GM-CSF without Flt3L. Flt3L has 
been used for the sequential differentiation of BM cells presumably because it 
improves hematopoietic stem cell (HSC) survival in vitro [6] and in vivo [72].  
Servet-Delprat et al. focused on Flt3L supplemented cells and did not delve into un-
supplemented cells. The group estimated 20% microglia from the number of ramified 
cells, which is confirmed by our results for ACM, GM-CSF, Flt3L supplemented cells. 
However, much higher microglia ‘yield’ can be obtained in the absence of Flt3L. In 
fact, we demonstrate that supplementation with Flt3L diminishes microglia 
differentiation: where Flt3L is added by itself or in combination with ACM, GM-CSF, 
the number of cells showing microglia markers, as well as the capacity for brain 
migration, phacocytosis and oxidative burst decreases. The differentiation protocols 
investigated here rely on using the supernatant at day 11 to select for non-adherent 
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progenitor cells, which are then cultured in the presence of ACM for another 6 days. 
The tactic is to first obtain a relatively pure progenitor population, which then 
differentiates in part into adherent microglia. Flt3L has been shown to expand HSC 
and to transiently increase adhesion of HSC in culture. It might play a role in 
mobilization of HSC to the blood stream [73]. Therefore the amount of microglia 
progenitor cells in the supernatant of the 11th day bone marrow culture might be 
decreased. In addition, Flt3L combined with GM-CSF has been shown to enhance 
dendritic cell differentiation [72, 74]. These factors may explain why Flt3L 
supplementation yields a lower fraction of functional in vitro-derived microglia.  
 
Co-culture with Living Brain Tissue 
 
Co-culture: Microglia derived from adult stem cells have to be able to migrate, 
survive and integrate into living brain tissue. In pre-transplantation studies we 
checked these functions by co-culturing differentiated microglia of several protocols 
with organotypic hippocampal brain slices (Paper 1 and 2 and data not shown) 
Survival: We could show here that our differentiated microglia survived and 
proliferated in co-cultures with organotypic brain slices for at least 10 days. 
Migration: Most cells migrated into the brain slice tissue superficially, while in vitro 
derived (ACM/GM-CSF, but without Flt3L) microglia migrated deepest into the tissue. 
It is known that the majority of primary microglia or BV2 cells just migrate over the 
surface layer of brain tissues under non-inflammatory conditions while a 
subpopulation migrates into the tissue [75-77]. Directed migration towards sites of 
injury induced by NMDA on the surface of brain slice cultures has been shown for 
primary microglia [76]. The damaged surface of the brain slice cultures even attracts 
slice internal microglia showing directed migration to the surface [75].  
Morphology: The differentiated microglia in co-culture showed both amoeboid and 
rounded morphologies, suggesting an activated state. They did not show pronounced 
ramification after 10 days. It is known that microglia of the brain itself move to the 
damaged surface after brain slices are cut [76]. It might be suspected that the seeded 
microglia similarly are activated by the damage and take part in removing debris. This 
would also explain the round cell shapes in co-culture, which only slowly settle to 
amoeboid shapes after 10 days. 
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Phagocytosis: The disappearance of cell debris stained with PI over time might be 
interpreted as phagocytic activity of the seeded cells. However, it could also be 
caused by the brains own microglia [75] or simply by medium changes which washed 
the cell debris away. 
 
Transplantation, Cell Tracking and Stereology 
 
Transplantation: In healthy, young animals migration of cells across the BBB is 
absent or low. However, it is present in the lesioned, diseased and inflamed brain 
[43, 46, 78]. A permeable blood brain barrier and inflammation in old age might 
change the migration behaviour in old age [79, 80]. Therefore, we hypothesized that 
transplantation in diseased or older animals might allow such migration (Paper 3).  
We transplanted NA-BMC and MSC intravenously in young (2-3 months), adult (12 
months) C57BL/6 mice and Alzheimer mice (9 months) (C57BL/6J TgN (Thy1-
APPKM670/671NL; Thy1-PS1L166P)). 
Cell Tracking: The cells were tracked by RT-PCR based detection of male DNA in 
tissue samples of sex mismatched hosts. After a follow up of 7 days, NA-BMC, 
transplanted intravenously in adult (12 months) mice, could be found in bone marrow 
and lungs but not in the brain and liver. Intravenous MSC could not be detected in 
bone marrow, liver, lung and brain of adult mice (Data not shown). This cell tracking 
method is sensitive, however, it is known that under healthy conditions few cells 
migrate to the brain and cross the BBB (Paper 3). Many of such systemically 
transplanted cells invade other tissues and larger cells become stuck in the lungs – 
as we did observe. Also, the comparatively low number of transplanted cells in 
absence of irradiation makes engraftment and detection harder. 
Stereology: The transplantation of NA-BMC and MSC did not significantly influence 
microglia activity in the brain as measured by stereology (Additional Data). Since 
both cell types could not be found in the brain such effects can not be expected or 
would be indirect. For example, MSC in sufficient numbers regulate the immune 
system organism wide [3, 21]. 
The method of microglia activity measurement – co-expression of microglia markers 
(Iba-1) and activity markers (MHC-II) – has sucessfully been used by other groups 
[81] but has several drawbacks. First, MHC-II is often expressed on the protusions of 
microglia and can, therefore, not clearly be linked to a certain microglia – the method 
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might systematically under- or overestimate ‘activity’ of microglia. Furthermore, the 
chosen markers might not completely coincide with the actual population of ‘active’ 
microglia or only catch one aspect of microglia activation – in the case of MHC-II 
phagocytosis. 
Stereology does, however, avoid many of the pitfalls present in less systematic 
counting of cells, such as the largely arbitrary choice of the region in which cells are 
counted or the problem of shrinking, expanding or shearing of biological tissues, The 
resulting errors are systematic, and therefore would not appear as statistical variation 
between several measured samples but rather as significant, false positive 
differences between experimental groups.   
Age related Changes: We could, however, observe age related changes in 
microglia numbers and activity between young and adult C57BL/6 mice (Additional 
Data). 
Microglia activity is significantly stronger in adult animals (52% compared to 25% in 
young animals). This microglia activity was defined after Sheffield et al. [81] as 
expression of MHC-II on the cell body of the microglia, defined as Iba-1 positive cells. 
The rise in activity is in line with observations by other groups [81]. 
The numbers of microglia in previous stereological studies [24, 82] were estimated to 
be about 37000 in the Dentate Gyrus region. We estimated the number in a region 
spanning the whole inside of Cornu Ammonis and Dentate Gyrus in both 
hemispheres. We would, therefore, roughly expect 60000 microglia in one 
hemisphere and 120000 in both. This is consistent with our results. 
We observe an increase of absolute microglia numbers in the hippocampus of adult 
female animals (93938) compared to young female animals (67490). However, also 
the size of the hippocampus increases. The difference in microglia number vanishes 
if the density of microglia is calculated. It might be suspected that the change is 
caused by normal growth of the hippocampus. 
Previous papers investigating the brain using stereological methods have reported an 
increasing number of microglia in the brain of female, but not male, mice with age. 
Mouton et al. saw an increase from 55000 to 69000 microglia in a Cornu Ammonis 
region [24] between young (4-6 months) and adult (13-14 months) female mice. 
However, the numbers between adult (13-14 months) and old (20-24 months) female 
mice stayed constant. It has been hypothesized that this is caused by inflammation or 
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sex hormones [24]. Other groups, however, have observed a diminishing effect of 
estrogen on microglia numbers.  
 
Outlook 
 
Microglia Differentiation: Our results and the results of others show the feasibility of 
deriving microglia from bone marrow [4-6]. The cells can now be continuously 
produced using the established optimized protocol. 
In vitro differentiated microglia need to be able to perform functions of primary 
microglia. We proved here the function (Phagocytosis, oxidative burst) of the derived 
cells. It becomes apparent here that differentiation according to markers is 
misleading and could result in cells not able to perform expected functions after 
transplantation. 
Co-culture with Living Brain Tissue: The differentiated microglia migrated, 
survived and showed function in living brain slices. However, they did not migrate 
deeply, but only in the immediate surface of the brain slices, although this could be 
caused by the surface injury induced by cutting the brain slices. This indicates that 
they could, in principle, if they invade the brain in circumstances that allow migration 
(Lesion, plaques, irradiation), perform the expected function. Differentiated microglia 
did, however, not ramify and down-regulate in co-culture. This could also be due to 
the injury induced by cutting the brain slices. Also, the harvesting (trypsinization) of 
cells could both hinder later ramification or activate the cells for a longer time. 
Transplantation, Cell Tracking: First transplantations of microglia progenitors did 
result in detectable cells in the bone marrow, but not in the brain, showed up 
regulation of neurogenesis (Data not shown) but did not influence microglia activity in 
adult Alzheimer models significantly. A longer follow up period and transplantation in 
older animals might allow the detection of significant effects. Life long replenishment 
of microglia is hypothesized to take place at a slow rate. The detection of NA-BMCs 
in the bone marrow of non-irradiated, transplanted animals is encouraging - over a 
longer period of time cells could proliferate and slowly turn over microglia in the brain 
to a larger extent.  
Stereology: We could measure changes in microglia activity and number with age 
using stereological methods. However, we could not detect a significant effect of our 
transplantations. Such stereological assessment of immune cell activity is time 
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consuming but might offer an interesting additional method to cross check other 
measurements of inflammation. It allows to obtain absolute instead of relative results. 
Also, the differences between the age controls would quite certainly be more 
pronounced in older mice. Then, regulatory effects of transplanted cells could 
become more easily detectable. 
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8. Summary 
 
Goals: Alzheimer and Multiple Sclerosis have been linked to a deterioration of the 
resident microglia cell population with age [1]. Therefore, we investigated here the 
differentiation of adult stem cells (mouse bone marrow) to microglia and potential 
application of these cells in a cell therapy. 
Differentiation of Microglia: We screened several protocols for microglia 
differentiation. As the best protocol a culture of BM over 11 days, subsequent 
flushing off of non-adherent cells and differentiation in a combination of astrocyte-
conditioned medium (ACM) and granulocyte/monocyte colony-stimulating factor (GM-
CSF), emerged. 
The cells showed long and branched processes and ramification, a morphology 
similar to primary microglia. They expressed antigens typical for primary microglia 
and macrophages. We could demonstrate that in vitro differentiated microglia are 
able to perform functions like phagocytosis and oxidative burst. 
We noticed that our controls not supplemented with FMS-like tyrosine-kinase-3 ligand 
(Flt3L) were differentiating much better. The effect of Flt3L supplementation had not 
been the focus of previous papers [6]. This negative effect is however not surprising. 
The reported functions of Flt3L, namely hematopoietic stem cells (HSC) survival, 
adhesion and dendritic cell differentiation point to a possible interference with 
microglia differentiation. 
Co-culture with Living Brain Tissue: We co-cultured the differentiated microglia 
with living brain slices. The cells survived and proliferated in co-culture. They also 
migrated into the immediate surface of the tissue. There are indications of phagocytic 
activity of the differentiated microglia in co-culture. 
Transplantation, Cell Tracking and Stereology: We transplanted non-adherent 
bone marrow cells (‘Microglia progenitors’) and MSC intraveneously in young (2-3 
months), adult (12 months) mice and Alzheimer models. We could detect NA-BMCs 
in bone marrow and lung but not in liver and brain. 
The influence of cell transplantation on the activation of microglia in the brain was 
investigated using stereology. Stereological estimates show that NA-BMCs and 
MSCs do not regulate microglia activity significantly (P = 0.08). 
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We also wanted to investigate age related changes in general. We observed robust 
changes between young and adult control animals. The activity of microglia was 
significantly higher in adult animals compared to young animals. Such a higher MHC-
II expression in aged microglia has also been observed by other groups using non-
stereological methods [81]. 
The number of microglia increased significantly in adult female compared to young 
female mice. This has been reported previously in female, but not in male, mice. It 
was suggested that sex hormones or inflammation in age might cause this difference 
[24]. However, other groups reported a negative effect of these hormones on 
microglia proliferation [83]. Our results show that the density of microglia remained 
the same between adult and young animals and that the hippocampus volume 
increased. This indicates that normal growth of the brain takes place.  
Outlook: We could show here that in vitro differentiated microglia are able to perform 
typical functions of primary microglia. They are phagocytic, perform oxidative burst, 
migrate into brain tissue and show morphology of primary microglia. In vitro derived 
microglia need to demonstrate the functional capacity of ‘real’ microglia cells and this 
research makes some contributions towards this aim. However, before such cells are 
deemed suitable and safe for transplantation extensive further tests will be required. 
 
8. Zusammenfassung 
 
Ziele: Alzheimer und Multiple Sklerose könnten mit einem Verfall und 
Funktionsverlust der residenten Mikroglia im Alter zusammenhängen [1]. Deshalb 
untersuchten wir hier die Differenzierung von adulten Stammzellen (Maus 
Knochenmark) zu Mikroglia und die potentielle Anwendung in einer Zelltherapie. 
Differenzierung von Mikroglia: Wir verglichen experimentell eine Reihe von 
Protokollen zur Differenzierung von Mikroglia. Als bestes Protokoll stellte sich eine 
Kultur von Knochenmark über 11 Tage, nachfolgendes Abspülen nicht adherenter 
Zellen und deren Differenzierung in einer Kombination von Astrozyten-
konditioniertem Medium (ACM) und Granulozyten/Monozyten Kolonien-
stimulierenden Faktor (GM-CSF) heraus. 
Die Zellen zeigten lange und verästelte Fortsätze, eine Morphologie ähnlich der von 
primären Mikroglia. Sie exprimierten typische Antigene primärer Mikroglia und 
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Makrophagen. Wir konnten zeigen dass in vitro differenzierte Mikroglia in der Lage zu 
Phagozytose und oxidativem Burst sind. 
Wir bemerkten dass unsere Kontrollen, die nicht mit FMS-ähnliche Tyrosinkinase-3 
Ligand (Flt3L) kultiviert wurden, viel besser differenzierten. Der Effekt von Flt3L 
Zugabe auf Mikroglia Differenzierung war nicht Fokus vorhergehender Arbeiten [6]. 
Dieser negative Effekt ist allerdings nicht überraschend. Die bekannten Funktionen 
von Flt3L, beispielsweise als Faktor für das Überleben von hämatopoietischen 
Stammzellen (HSC), Adhäsion und Differenzierung von dendritischen Zellen, weisen 
auf eine mögliche Beeinträchtigung der Differenzierng von Mikroglia hin. 
Ko-Kultur mit Lebendem Hirngewebe: Wir ko-kultivierten die in vitro differenzierten 
Mikroglia zusammen mit lebendem Hirngewebe. Die Zellen überlebten und 
vermehrten sich in Ko-Kultur. Sie migrierten in die unmittelbare Oberfäche des 
Gewebes. Es gab auch Anzeichen für phagozytische Aktivität der in vitro 
differenzierten Mikroglia in Ko-Kultur. 
Transplantation, Zelltracking und Stereologie: Wir transplantierten nicht-
adherente Knochenmarkszellen (‘Mikroglia Vorläufer’) und MSC intravenös in junge 
(2-3 Monate), adulte (12 monate) und Alzheimer Mäuse. Wir konnten NA-BMCs in 
Knochenmark und Lunge aber nicht in Leber und Gehirn nachweisen. 
Der Einfluss der Transplantationen auf die Aktivität von Mikroglia im Gehirn wurde 
mittels Stereologie gemessen. Stereologische Schätzungen zeigen dass NA-BMCs 
und MSCs die Aktivität von Mikroglia im Gehirn nicht signifikant beeinflussen (P = 
0.08). 
Wir wollten auch altersabhängige Veränderungen allgemein untersuchen. Wir 
bemerkten ausgeprägte Veränderungen zwischen jungen und adulten Kontrolltieren. 
Die Aktivität von Mikroglia im Gehirn war signifikant höher in adulten Tieren 
verglichen mit jungen. Solch eine höhere MHC-II Expression in gealterten Mikroglia 
wurde auch von anderen Gruppen mit nicht-stereologischen Methoden gemessen 
[81]. 
Die Zahl der Mikroglia im Hippocampus erhöhte sich signifikant in adulten weiblichen, 
verglichen mit jungen weiblichen, Mäusen. Dies wurde auch in der Vergangenheit in 
weiblichen, aber nicht in männlichen, Mäusen festgestellt. Dieser Unterschied könnte 
durch Sexualhormone oder Inflammation in fortgeschrittenem Alter verursacht 
werden [24]. Andere Gruppen berichteten allerdings dass solche Hormone einen 
negativen Effekt auf die Mikroglia Proliferation haben [83]. Unsere Ergebnisse zeigen 
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dass die Dichte von Mikroglia zwischen adulten und jungen Tieren gleich bleibt, 
allerdings das Hippocampus Volumen zunimmt. Das könnte ein Hinweis darauf sein 
dass normales Wachstum des Gehirns stattfindet. 
Ausblick: Wir konnten hier zeigen dass in vitro differenzierte Mikroglia typische 
Funktionen von primären Mikroglia aufweisen. Sie sind phagozytisch, zeigen 
oxidativen Burst, Migration in lebendes Hirngewebe und Morphologie ähnlich der 
primärer Mikroglia. In vitro differenzierte Mikroglia müssen die Funktion ‘echter’ 
Microglia Zellen ausüben können und diese Arbeit leistet dazu einen Beitrag. Bevor 
die Zellen allerdings als geeignet und sicher für eine Transplantation angesehen 
werden können sind umfangreiche weitere Tests notwendig. 
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10.1. Abbreviations 
 
ACM   Astrocyte Conditioned Medium 
AFF488  Alexa Fluor 488 
ALP   Alkaline Phosphatase 
ASBI   6-Bromo-2-phospho-hydroxy-3-naphthoic acid o-anisidide 
Balb/c   Mouse Strain 
Balb/c SR/CR Mouse Strain 
BBB   Blood Brain Barrier 
BDF1   Mouse Strain 
BM   Bone Marrow 
BMC   Bone Marrow Cells 
BMT   Bone Marrow Transplantation 
BV2   Microglia Cell Line 
C57BL/6  Mouse Strain 
CBA-J   Mouse Strain 
CD   Cluster of Differentiation 
CE   Coefficient of Error 
CFU-f   Fibroblast Colony Forming Unit 
CNS   Central Nervous System 
CPS   Cryo Protection Solution 
DAP12  DNAX Activating Protein 12kDa 
DAPI   4’,6-diamidino-2-phenylindole 
DHR123  Dihydrorhodamin 123 
DiO   3,3’-dioctadecyloxacarboxyanine perchlorate 
DMEM  Dulbecco Minimal Essential Medium 
DPBS   Dulbecco’s Phosphate Buffered Saline 
DPX   Distrene-80, Plasticizer, Xylene 
ESC   Embryonic Stem Cells 
FCS   Fetal Calf Serum 
Flt3L   FMS-Like Tyrosine kinase 3 Ligand 
FNA   Faciel Nerve Axotomy 
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FSC   Forward Scatter 
FSN   Fluorescence Signal Noise Ratio 
GFP   Green Fluorescent Protein 
GM-CSF  Granulocyte/Monocyte Colony Stimulating Factor 
HBSS   Hank’s Balanced Salt Solution 
HSC   Hematopoietic Stem Cells 
HSPC   Hematopoietic Stem and Progenitor Cells 
Iba-1   Ionized calcium-Binding Adapter molecule-1  
IL   Interleukin 
LPS   Lypopolysaccharides 
M-CSF  Macrophage Colony Simulating Factor 
MCP-1  Monocyte Chemoattractant Protein 1 
MHC-II  Major Histocompatibility Complex II# 
MP   Microglia Progenitors 
MSC   Mesenchymal Stem Cells 
NA-BMC  Non-Adherent Bone Marrow Cells 
NADPH  Nicotinamidadenindinucleotid Phosphat 
NBT   Nitro Blue Tetrazolium 
NMDA  N-Methyl-D-Aspartic Acid 
NO   Nitric Oxygen 
NRBC   Nucleated Red Blood Cells 
OHSC   Organotypic Hippocampal Slice Cultures 
PBS   Phosphate Buffered Saline 
PE   Phycoerythrin 
PFA   Paraformaldehyde 
Pen/Strep  Penicillin/Streptomycin 
PI   Propidium Iodide 
PMA   Phorbol Myristic Acid 
RPE   R-Phycoerythrin 
ROS   Reactive Oxygen System 
SCF   Stem Cell Factor 
SE   Standard Error 
SSC   Side Scatter 
TGF-beta  Tumor Growth Factor beta 
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TLR   Toll Like Receptor 
Tmem176b  Transmembrane Protein 176b 
TNF-alpha  Tumor Necrosis Factor alpha 
TREM2  Triggering Receptor 
Tris   Tris (hydroxymethyl)-aminomethan 
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